Patent Application
20220119825
The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Oct. 27, 2021, is named 070050 6561 SL.txt and is 434,557 bytes in size.
The present disclosure relates to intercellular signaling pathways between genetically-engineered cells and, more specifically, to a scalable G-protein coupled receptor (GPCR)-ligand intercellular signaling system.
Genetic engineering techniques have been applied to create specialized biological systems from living cells. However, the development of higher-order cellular networks responsive to signals in a coordinated fashion has been hampered due to a need for an adaptable cell signaling language. Certain approaches based on quorum sensing or synthetic receptors are not scalable, and are not necessarily suitable for long-range communication between cells. Therefore, an improved versatile, scalable intercellular signaling language for cell-cell communication is needed.
The present disclosure provides a genetically-engineered cell that expresses at least one heterologous G-protein coupled receptor (GPCR) and/or at least one heterologous secretable GPCR peptide ligand. For example, but not by way of limitation, a genetically-engineered cell can express at least one heterologous GPCR, express at least one secretable GPCR peptide ligand or express at least one heterologous GPCR and at least one secretable GPCR peptide ligand. In certain embodiments, the amino acid sequence of the heterologous GPCR is at least about 75% homologous to an amino acid sequence comprising any one of SEQ ID NOs: 117-161 or an amino acid sequence provided in Table 11 and/or is encoded by a nucleotide sequence that is at least about 75% homologous to a nucleotide sequence comprising any one of SEQ ID NOs: 168-211. In certain embodiments, the amino acid sequence of the GPCR peptide ligand is at least about 75% homologous to an amino acid sequence comprising any one of SEQ ID NOs: 1-116 or an amino acid sequence provided in Table 12 and/or encoded by a nucleotide sequence that is about 75% homologous to a nucleotide sequence comprising any one of SEQ ID NOs: 215-230. In certain embodiments, the secretable GPCR ligand and/or the heterologous GPCR are identified and/or derived from a eukaryotic organism, e.g., a yeast. In certain embodiments, the heterologous GPCR is selectively activated by a ligand, e.g., a peptide, a protein or portion thereof, a toxin, a small molecule, a nucleotide, a lipid, a chemical, a photon, an electrical signal or a compound. In certain embodiments, the ligand is a peptide.
The present disclosure further provides an intercellular signaling system that includes two or more, three or more, four or more or five or more genetically-engineered cells disclosed herein. In certain embodiments, an intercellular signaling system of the present disclosure includes a first genetically-engineered cell expressing at least one secretable G-protein coupled receptor (GPCR) ligand and a second genetically-engineered cell expressing at least one heterologous GPCR. In certain embodiments, the amino acid sequence of the heterologous GPCR is at least about 75% homologous to an amino acid sequence comprising any one of SEQ ID NOs: 117-161 or an amino acid sequence provided in Table 11 and/or is encoded by a nucleotide sequence that is at least about 75% homologous to a nucleotide sequence comprising any one of SEQ ID NOs: 168-211. In certain embodiments, the amino acid sequence of the secretable GPCR ligand is at least about 75% homologous to an amino acid sequence comprising any one of SEQ ID NOs: 1-116 or an amino acid sequence provided in Table 12 and/or is encoded by a nucleotide sequence that is about 75% homologous to a nucleotide sequence comprising any one of SEQ ID NOs: 215-230. In certain embodiments, the secretable GPCR ligand and/or the heterologous GPCR are identified and/or derived from a eukaryotic organism. In certain embodiments, the secretable GPCR ligand is selected from the group consisting of a protein or portion thereof and a peptide. In certain embodiments, the secretable GPCR ligand of the first genetically-engineered cell selectively activates the heterologous GPCR of the second genetically-engineered cell. Alternatively, the secretable GPCR ligand of the first genetically-engineered cell does not activate the heterologous GPCR of the second genetically-engineered cell. For example, but not by way of limitation, the heterologous GPCR of the second genetically-engineered cell is activated by an exogenous ligand, e.g., a peptide, a protein or portion thereof, a toxin, a small molecule, a nucleotide, a lipid, chemicals, a photon, an electrical signal and a compound.
In certain embodiments, the second genetically-engineered cell further expresses at least one secretable GPCR ligand and/or the first genetically-engineered cell further expresses at least one heterologous GPCR. For example, but not by way of limitation, the first genetically-engineered cell of an intercellular signaling system expresses at least one secretable GPCR ligand and at least one heterologous GPCR. In certain embodiments, the second genetically-engineered cell of such a system expresses at least one secretable GPCR ligand and at least one heterologous GPCR. In certain embodiments, the secretable GPCR ligand expressed by the second genetically-engineered cell is different from the secretable GPCR ligand expressed by the first genetically-engineered cell, e.g., selectively activate different GPCRs. In certain embodiments, the heterologous GPCR expressed by the first genetically-engineered cell is different from the heterologous GPCR expressed by the second genetically-engineered cell, e.g., are selectively activated by different ligands. In certain embodiments, the secretable GPCR ligand expressed by the second genetically-engineered cell does not activate the heterologous GPCR expressed by the second genetically-engineered cell. In certain embodiments, the secretable GPCR ligand expressed by the first genetically-engineered cell does not activate the heterologous GPCR expressed by the first genetically-engineered cell. In certain embodiments, the secretable GPCR ligand of the first genetically-engineered cell selectively activates the heterologous GPCR of the second genetically-engineered cell. In certain embodiments, the secretable GPCR ligand of the first genetically-engineered cell does not activate the heterologous GPCR of the second genetically-engineered cell. In certain embodiments, the secretable GPCR ligand expressed by the second genetically-engineered cell selectively activates the heterologous GPCR expressed by the first genetically-engineered cell. In certain embodiments, the secretable GPCR ligand expressed by the second genetically-engineered cell does not activate the heterologous GPCR expressed by the first genetically-engineered cell. In certain embodiments, the secretable GPCR ligand expressed by the second genetically-engineered cell and/or the first genetically-engineered cell selectively activates a GPCR expressed on a third cell.
In certain embodiments, one or more endogenous GPCR genes and/or endogenous GPCR ligand genes of one or more genetically-engineered cells disclosed herein, e.g., the first genetically-engineered cell and/or the second genetically-engineered cell, are knocked out. In certain embodiments, one or more of the genetically-engineered cells disclosed herein, e.g., the first genetically-engineered cell and/or the second genetically-engineered cell, further include a nucleic acid that encodes a sensor and/or a nucleic acid that encodes a detectable reporter. In certain embodiments, one or more of the genetically-engineered cells disclosed herein, e.g., the first genetically-engineered cell and/or the second genetically-engineered cell, further include a nucleic acid that encodes a product of interest.
In certain embodiments, an intercellular signaling system of the present disclosure further includes a third genetically-engineered, a fourth genetically-engineered cell, a fifth genetically-engineered cell, a sixth genetically-engineered cell, a seventh genetically-engineered cell and/or an eighth genetically-engineered cell or more. In certain embodiments, each genetically-engineered cell expresses at least one heterologous GPCR and/or at least one secretable GPCR ligand. In certain embodiments, each of the heterologous GPCRs are different, e.g., are selectively activated by different ligands, and/or each of the secretable GPCR ligands are different, e.g., selectively activate different GPCRs. Alternatively and/or additionally, one or more heterologous GPCRs are the same and/or one or more of the secretable GPCR ligands are the same.
The present disclosure further provides for an intercellular signaling system that includes a first genetically-engineered cell including: (i) a nucleic acid encoding a first heterologous G-protein coupled receptor (GPCR); and/or (ii) a nucleic acid encoding a first secretable GPCR ligand; and a second genetically-engineered cell including: (i) a nucleic acid encoding a second heterologous GPCR; and/or (ii) a nucleic acid encoding a second secretable GPCR ligand. In certain embodiments, the first GPCR and/or the second GPCR is at least about 75% homologous to an amino acid sequence comprising any one of SEQ ID NOs: 117-161 or an amino acid sequence provided in Table 11 and/or is encoded by a nucleotide sequence that is at least about 75% homologous to a nucleotide sequence comprising any one of SEQ ID NOs: 168-211. In certain embodiments, the first and/or second secretable GPCR peptide ligand is at least about 75% homologous to an amino acid sequence comprising any one of SEQ ID NOs: 1-116 or an amino acid sequence provided in Table 12 and/or is encoded by a nucleotide sequence that is about 75% homologous to a nucleotide sequence comprising any one of SEQ ID NOs: 215-230. In certain embodiments, the first secretable GPCR ligand of the first genetically-engineered cell selectively activates the second heterologous GPCR of the second genetically-engineered cell, the second secretable GPCR ligand of the second genetically-engineered cell selectively activates the first heterologous GPCR of the first genetically-engineered cell, the second secretable GPCR ligand of the second genetically-engineered cell selectively does not activate the first heterologous GPCR of the first genetically-engineered cell and/or the first heterologous GPCR and the second heterologous GPCR are selectively activated by different ligands.
In certain embodiments, the intercellular signaling system further includes a third genetically-engineered cell that includes a nucleic acid encoding a third heterologous GPCR; and/or a nucleic acid encoding a third secretable GPCR ligand. In certain embodiments, the first secretable GPCR ligand of the first genetically-engineered cell selectively activates the third heterologous GPCR of the third genetically-engineered cell and/or the second heterologous GPCR of the second genetically-engineered cell. In certain embodiments, the second secretable GPCR ligand of the second genetically-engineered cell selectively activates the third heterologous GPCR of the third genetically-engineered cell and/or the first heterologous GPCR of the first genetically-engineered cell. In certain embodiments, the third secretable GPCR ligand of the third genetically-engineered cell selectively activates the first heterologous GPCR of the first genetically-engineered cell and/or the second heterologous GPCR of the third genetically-engineered cell. In certain embodiments, the third secretable GPCR ligand of the third genetically-engineered cell does not activate the third heterologous GPCR of the third genetically-engineered cell. In certain embodiments, the first secretable GPCR ligand of the first genetically-engineered cell does not activate the first heterologous GPCR of the first genetically-engineered cell. In certain embodiments, the second secretable GPCR ligand of the second genetically-engineered cell does not activate the second heterologous GPCR of the second genetically-engineered cell.
The present disclosure further provides a kit that includes a genetically modified cell or an intercellular signaling system as disclosed herein. For example, but not by way of limitation, the genetically modified cell present within a kit of the present disclosure includes at least one heterologous G-protein coupled receptor (GPCR) and/or at least one heterologous secretable GPCR peptide ligand. In certain embodiments, the intercellular signaling system present within a kit of the present disclosure includes a first genetically-engineered cell expressing at least one secretable G-protein coupled receptor (GPCR) ligand; and a second genetically-engineered cell expressing at least one heterologous GPCR. Alternatively and/or additionally, the intercellular signaling system to be included in a kit of the present disclosure includes a first genetically-engineered cell that includes (i) a nucleic acid encoding a first heterologous G-protein coupled receptor (GPCR); and/or (ii) a nucleic acid encoding a first secretable GPCR ligand; and a second genetically-engineered cell that includes (i) a nucleic acid encoding a second heterologous GPCR; and/or (ii) a nucleic acid encoding a second secretable GPCR ligand. In certain embodiments, the amino acid sequence of the heterologous GPCR is at least about 75% homologous to an amino acid sequence comprising any one of SEQ ID NOs: 117-161 or an amino acid sequence provided in Table 11 and/or is encoded by a nucleotide sequence that is at least about 75% homologous to a nucleotide sequence comprising any one of SEQ ID NOs: 168-211. In certain embodiments, the amino acid sequence of the GPCR ligand or GPCR peptide ligand is at least about 75% homologous to an amino acid sequence comprising any one of SEQ ID NOs: 1-116 or an amino acid sequence provided in Table 12 and/or encoded by a nucleotide sequence that is about 75% homologous to a nucleotide sequence comprising any one of SEQ ID NOs: 215-230.
In another aspect, the present disclosure provides an intercellular signaling system for spatial control of gene expression and/or temporal control of gene expression, for the generation of pharmaceuticals and/or therapeutics, for performing computations, as a biosensor and for the generation of a product of interest. In certain embodiments, the intercellular signaling system includes a first genetically-engineered cell expressing at least one secretable G-protein coupled receptor (GPCR) ligand; and a second genetically-engineered cell expressing at least one heterologous GPCR. In certain embodiments, the intercellular signaling system includes a first genetically-engineered cell including: (a) a nucleic acid encoding a first heterologous G-protein coupled receptor (GPCR); and/or (b) a nucleic acid encoding a first secretable GPCR ligand; and a second genetically-engineered cell including: (a) a nucleic acid encoding a second heterologous GPCR; and/or (b) a nucleic acid encoding a second secretable GPCR ligand. In certain embodiments, the amino acid sequence of the heterologous GPCR is at least about 75% homologous to an amino acid sequence comprising any one of SEQ ID NOs: 117-161 or an amino acid sequence provided in Table 11 and/or is encoded by a nucleotide sequence that is at least about 75% homologous to a nucleotide sequence comprising any one of SEQ ID NOs: 168-211. In certain embodiments, the amino acid sequence of the secretable GPCR ligand is at least about 75% homologous to an amino acid sequence comprising any one of SEQ ID NOs: 1-116 or an amino acid sequence provided in Table 12 and/or is encoded by a nucleotide sequence that is about 75% homologous to a nucleotide sequence comprising any one of SEQ ID NOs: 215-230
In certain embodiments, the genetically-engineered cells disclosed herein are independently selected from the group consisting of a mammalian cell, a plant cell and a fungal cell. For example, but not by way of limitation, the genetically-engineered cells are fungal cells, fungal cells from the phylum Ascomycota and/or fungal cells independently selected from the group consisting of Saccharomyces cerevisiae, Saccharomyces castellii, Vanderwaltozyma polyspora, Torulaspora delbrueckii, Saccharomyces kluyveri, Kluyveromyces lactis, Zygosaccharomyces rouxii, Zygosaccharomyces bailii, Candida glabrata, Ashbya gossypii, Scheffersomyces stipites, Komagataella (Pichia) pastoris, Candida (Pichia) guilliermondii, Candida parapsilosis, Candida auris, Yarrowia lipolytica, Candida (Clavispora) lusitaniae, Candida albicans, Candida tropicalis, Candida tenuis, Lodderomyces elongisporous, Geotrichum candidum, Baudoinia compniacensis, Schizosaccharomyces octosporus, Tuber melanosporum, Aspergillus oryzae, Schizosaccharomyces pombe, Aspergillus (Neosartorya) fischeri, Pseudogymnoascus destructans, Schizosaccharomyces japonicus, Paracoccidioides brasiliensis, Mycosphaerella graminicola, Penicillium chrysogenum, Aspergillus nidulans, Phaeosphaeria nodorum, Hypocrea jecorina, Botrytis cinereal, Beauvaria bassiana, Neurospora crassa, Sporothrix scheckii, Magnaporthe oryzea, Dactylellina haptotyla, Fusarium graminearum, Capronia coronate and combinations thereof.
In certain embodiments, an intercellular signaling system of the present disclosure has a topology selected from the group consisting of a daisy chain network topology, a bus type network topology, a branched type network topology, a ring network topology, a mesh network topology, a hybrid network topology, a star type network topology and a combination thereof.
In certain embodiments, the product of interest is selected from the group consisting of hormones, toxins, receptors, fusion proteins, regulatory factors, growth factors, complement system factors, enzymes, clotting factors, anti-clotting factors, kinases, cytokines, CD proteins, interleukins, therapeutic proteins, diagnostic proteins, enzymes, biosynthetic pathways, antibodies and combinations thereof.
In another aspect, the present disclosure provides a method for the identification of a G-protein coupled receptor (GPCR) and/or a GPCR ligand to be expressed in a genetically-engineered cell. In certain embodiments, the method for identifying a GPCR includes searching a protein and/or genomic database and/or literature for a protein and/or a gene with homology to: (i) a S. cerevisiae Ste2 receptor and/or Ste3 receptor; (ii) a GPCR having an amino acid sequence comprising any one of SEQ ID NOs: 117-161; (iii) a GPCR having an amino acid sequence provided in Table 11; and/or (iv) a GPCR encoded by a nucleotide sequence comprising any one of SEQ ID NOs: 168-211. In certain embodiments, the method for identifying a GPCR ligand includes searching a protein and/or genomic database and/or literature for a protein, peptide and/or a gene with homology to: (i) a GPCR peptide ligand having an amino acid sequence comprising any one of SEQ ID NOs: 1-116; (ii) a GPCR peptide ligand comprising an amino acid sequence provided in Table 12; (iii) a GPCR peptide ligand encoded by a nucleotide sequence comprising any one of SEQ ID NOs: 215-230 to identify a GPCR ligand; and/or (iv) a yeast pheromone or a motif thereof. The present disclosure further provides a genetically-engineered cell that expresses a GPCR and/or GPCR ligand identified by the methods disclosed herein.
The present disclosure relates to the use of G-protein coupled receptor (GPCR)-ligand pairs to promote intercellular signaling between genetically-engineered cells. For example, but not by way of limitation, the present disclosure provides intercellular signaling systems that include two or more genetically-engineered cells that communicate with each other, and kits thereof. In particular, the scalable GPCR-peptide intercellular signaling system described herein is generally useful for engineering multicellular systems based on unicellular organisms, e.g., yeast.
For clarity, but not by way of limitation, the detailed description of the presently disclosed subject matter is divided into the following subsections:
I. Definitions;
II. G protein-coupled receptors (GPCRs) and cognate ligands;
III. Cells;
IV. Intracellular signaling networks;
V. Methods of Use;
VI. Kits; and
VII. Exemplary Embodiments.
The terms used in this specification generally have their ordinary meanings in the art, within the context of this disclosure and in the specific context where each term is used. Certain terms are discussed below, or elsewhere in the specification, to provide additional guidance to the practitioner in describing the compositions and methods of the present disclosure and how to make and use them.
As used herein, the use of the word “a” or “an” when used in conjunction with the term “comprising” in the claims and/or the specification can mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.”
The terms “comprise(s),” “include(s),” “having,” “has,” “can,” “contain(s),” and variants thereof, as used herein, are intended to be open-ended transitional phrases, terms or words that do not preclude additional acts or structures. The present disclosure also contemplates other embodiments “comprising,” “consisting of” and “consisting essentially of,” the embodiments or elements presented herein, whether explicitly set forth or not.
The term “about” or “approximately” means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, “about” can mean within 3 or more than 3 standard deviations, per the practice in the art. Alternatively, “about” can mean a range of up to 20%, preferably up to 10%, more preferably up to 5%, and more preferably still up to 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, preferably within 5-fold, and more preferably within 2-fold, of a value.
The term “expression” or “expresses,” as used herein, refer to transcription and translation occurring within a cell, e.g., yeast cell. The level of expression of a gene and/or nucleic acid in a cell can be determined on the basis of either the amount of corresponding mRNA that is present in the cell or the amount of the protein encoded by the gene and/or nucleic acid that is produced by the cell. For example, mRNA transcribed from a gene and/or nucleic acid is desirably quantitated by northern hybridization. Sambrook et al., Molecular Cloning: A Laboratory Manual, pp. 7.3-7.57 (Cold Spring Harbor Laboratory Press, 1989). Protein encoded by a gene and/or nucleic acid can be quantitated either by assaying for the biological activity of the protein or by employing assays that are independent of such activity, such as western blotting or radioimmunoassay using antibodies that are capable of reacting with the protein. Sambrook et al., Molecular Cloning: A Laboratory Manual, pp. 18.1-18.88 (Cold Spring Harbor Laboratory Press, 1989).
As used herein, “polypeptide” refers generally to peptides and proteins having about three or more amino acids. In certain embodiments, the polypeptide comprises the minimal amount of amino acids that are detectable by a G-protein coupled receptor (GPCR). The polypeptides can be endogenous to the cell, or preferably, can be exogenous, meaning that they are heterologous, i.e., foreign, to the cell being utilized, such as a synthetic peptide and/or GPCR produced by a yeast cell. In certain embodiments, synthetic peptides are used, more preferably those which are directly secreted into the medium.
The term “protein” is meant to refer to a sequence of amino acids for which the chain length is sufficient to produce the higher levels of tertiary and/or quaternary structure. This is to distinguish from “peptides” that typically do not have such structure. Typically, the protein herein will have a molecular weight of at least about 15-100 kD, e.g., closer to about 15 kD. In certain embodiments, a protein can include at least about 50, about 60, about 70, about 80, about 90, about 100, about 200, about 300, about 400 or about 500 amino acids. Examples of proteins encompassed within the definition herein include all proteins, and, in general proteins that contain one or more disulfide bonds, including multi-chain polypeptides comprising one or more inter- and/or intrachain disulfide bonds. In certain embodiments, proteins can include other post-translation modifications including, but not limited to, glycosylation and lipidation. See, e.g., Prabakaran et al., WIREs Syst Biol Med (2012), which is incorporated herein by reference in its entirety.
As used herein the term “amino acid,” “amino acid monomer” or “amino acid residue” refers to organic compounds composed of amine and carboxylic acid functional groups, along with a side-chain specific to each amino acid. In particular, alpha- or α-amino acid refers to organic compounds in which the amine (—NH2) is separated from the carboxylic acid (—COOH) by a methylene group (—CH2), and a side-chain specific to each amino acid connected to this methylene group (—CH2) which is alpha to the carboxylic acid (—COOH). Different amino acids have different side chains and have distinctive characteristics, such as charge, polarity, aromaticity, reduction potential, hydrophobicity, and pKa. Amino acids can be covalently linked to form a polymer through peptide bonds by reactions between the carboxylic acid group of the first amino acid and the amine group of the second amino acid. Amino acid in the sense of the disclosure refers to any of the twenty plus naturally occurring amino acids, non-natural amino acids, and includes both D and L optical isomers.
The term “nucleic acid,” “nucleic acid molecule” or “polynucleotide” includes any compound and/or substance that comprises a polymer of nucleotides. Each nucleotide is composed of a base, specifically a purine- or pyrimidine base (i.e., cytosine (C), guanine (G), adenine (A), thymine (T) or uracil (U)), a sugar (i.e., deoxyribose or ribose), and a phosphate group. Often, the nucleic acid molecule is described by the sequence of bases, whereby said bases represent the primary structure (linear structure) of a nucleic acid molecule. The sequence of bases is typically represented from 5′ to 3′. Herein, the term nucleic acid molecule encompasses deoxyribonucleic acid (DNA) including, e.g., complementary DNA (cDNA) and genomic DNA, ribonucleic acid (RNA), in particular messenger RNA (mRNA), synthetic forms of DNA or RNA, and mixed polymers comprising two or more of these molecules. The nucleic acid molecule can be linear or circular. In addition, the term nucleic acid molecule includes both, sense and antisense strands, as well as single stranded and double stranded forms. Moreover, the herein described nucleic acid molecule can contain naturally occurring or non-naturally occurring nucleotides. Examples of non-naturally occurring nucleotides include modified nucleotide bases with derivatized sugars or phosphate backbone linkages or chemically modified residues. Nucleic acid molecules also encompass DNA and RNA molecules which are suitable as a vector for direct expression of an GPCR or secretable peptide of the disclosure in vitro and/or in vivo, e.g., in a yeast cell. Such DNA (e.g., cDNA) or RNA (e.g., mRNA) vectors, can be unmodified or modified. For example, mRNA can be chemically modified to enhance the stability of the RNA vector and/or expression of the encoded molecule.
As used herein, the term “vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
As used herein, the term “recombinant cell” refers to cells which have some genetic modification from the original parent cells from which they are derived. Such cells can also be referred to as “genetically-engineered cells.” Such genetic modification can be the result of an introduction of a heterologous gene (or nucleic acid) for expression of the gene product, e.g., a recombinant protein, e.g., GPCR, or peptide, e.g., secretable peptide.
As used herein, the term “recombinant protein” refers generally to peptides and proteins. Such recombinant proteins are “heterologous,” i.e., foreign to the cell being utilized, such as a heterologous secretory peptide produced by a yeast cell.
As used herein, “sequence identity” or “identity” in the context of two polynucleotide or polypeptide sequences makes reference to the nucleotide bases or amino acid residues in the two sequences that are the same when aligned for maximum correspondence over a specified comparison window. When percentage of sequence identity or similarity is used in reference to proteins, it is recognized that residue positions which are not identical often differ by conservative amino acid substitutions, where amino acid residues are substituted with a functionally equivalent residue of the amino acid residues with similar physiochemical properties and therefore do not change the functional properties of the molecule.
As used herein, “percentage of sequence identity” means the value determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window can include additions or deletions (gaps) as compared to the reference sequence (which does not include additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison, and multiplying the result by 100 to yield the percentage of sequence identity.
As understood by those skilled in the art, determination of percent identity between any two sequences can be accomplished using certain well-known mathematical algorithms. Non-limiting examples of such mathematical algorithms are the algorithm of Myers and Miller, the local homology algorithm of Smith et al.; the homology alignment algorithm of Needleman and Wunsch; the search-for-similarity-method of Pearson and Lipman; the algorithm of Karlin and Altschul, modified as in Karlin and Altschul. Computer implementations of suitable mathematical algorithms can be utilized for comparison of sequences to determine sequence identity. Such implementations include, but are not limited to: CLUSTAL, ALIGN, GAP, BESTFIT, BLAST, FASTA, among others identifiable by skilled persons.
As used herein, “reference sequence” is a defined sequence used as a basis for sequence comparison. A reference sequence can be a subset or the entirety of a specified sequence; for example, as a segment of a full-length protein or protein fragment. A reference sequence can be, for example, a sequence identifiable in a database such as GenBank and UniProt and others identifiable to those skilled in the art.
The term “operative connection” or “operatively linked,” as used herein, with regard to regulatory sequences of a gene indicate an arrangement of elements in a combination enabling production of an appropriate effect. With respect to genes and regulatory sequences, an operative connection indicates a configuration of the genes with respect to the regulatory sequence allowing the regulatory sequences to directly or indirectly increase or decrease transcription or translation of the genes. In particular, in certain embodiments, regulatory sequences directly increasing transcription of the operatively linked gene, comprise promoters typically located on a same strand and upstream on a DNA sequence (towards the 5′ region of the sense strand), adjacent to the transcription start site of the genes whose transcription they initiate. In certain embodiments, regulatory sequences directly increasing transcription of the operatively linked gene or gene cluster comprise enhancers that can be located more distally from the transcription start site compared to promoters, and either upstream or downstream from the regulated genes, as understood by those skilled in the art. Enhancers are typically short (50-1500 bp) regions of DNA that can be bound by transcriptional activators to increase transcription of a particular gene. Typically, enhancers can be located up to 1 Mbp away from the gene, upstream or downstream from the start site.
The term “secretable,” as used herein, means able to be secreted, wherein secretion in the present disclosure generally refers to transport or translocation from the interior of a cell, e.g., within the cytoplasm or cytosol of a cell, to its exterior, e.g., outside the plasma membrane of the cell. Secretion can include several procedures, including various cellular processing procedures such as enzymatic processing of the peptide. In certain embodiments, secretion, e.g., secretion of a GPCR ligand, can utilize the classical secretory pathway of yeast.
As would be understood by those skilled in the art, the term “codon optimization,” as used herein, refers to the introduction of synonymous mutations into codons of a protein-coding gene in order to improve protein expression in expression systems of a particular organism, such as a cell of a species of the phylum Ascomycota, in accordance with the codon usage bias of that organism. The term “codon usage bias” refers to differences in the frequency of occurrence of synonymous codons in coding DNA. The genetic codes of different organisms are often biased towards using one of the several codons that encode a same amino acid over others—thus using the one codon with, a greater frequency than expected by chance. Optimized codons in microorganisms, such as Saccharomyces cerevisiae, reflect the composition of their respective genomic tRNA pool. The use of optimized codons can help to achieve faster translation rates and high accuracy.
In the field of bioinformatics and computational biology, many statistical methods have been discussed and used to analyze codon usage bias. Methods such as the ‘frequency of optimal codons’ (Fop), the Relative Codon Adaptation (RCA) or the ‘Codon Adaptation Index’ (CAI) are used to predict gene expression levels, while methods such as the ‘effective number of codons’ (Nc) and Shannon entropy from information theory are used to measure codon usage evenness. Multivariate statistical methods, such as correspondence analysis and principal component analysis, are widely used to analyze variations in codon usage among genes. There are many computer programs to implement the statistical analyses enumerated above, including CodonW, GCUA, INCA, and others identifiable by those skilled in the art. Several software packages are available online for codon optimization of gene sequences, including those offered by companies such as GenScript, EnCor Biotechnology, Integrated DNA Technologies, ThermoFisher Scientific, among others known those skilled in the art. Those packages can be used in providing GPCR genetic molecular components and GPCR peptide ligand genetic molecular components with codon ensuring optimized expression in various intercellular signaling systems as will be understood by a skilled person.
The term “binding,” as used herein, refers to the connecting or uniting of two or more components by a interaction, bond, link, force or tie in order to keep two or more components together, which encompasses either direct or indirect binding where, for example, a first component is directly bound to a second component, or one or more intermediate molecules are disposed between the first component and the second component. Exemplary bonds comprise covalent bond, ionic bond, van der Waals interactions and other bonds identifiable by a skilled person. In certain embodiments, the binding can be direct, such as the production of a polypeptide scaffold that directly binds to a scaffold-binding element of a protein. In certain embodiments, the binding can be indirect, such as the co-localization of multiple protein elements on one scaffold. In certain embodiments, binding of a component with another component can result in sequestering the component, thus providing a type of inhibition of the component. In certain embodiments, binding of a component with another component can change the activity or function of the component, as in the case of allosteric or other interactions between proteins that result in conformational change of a component, thus providing a type of activation of the bound component. Examples described herein include, without limitation, binding of a GPCR ligand, e.g., peptide ligand, to a GPCR.
The term “selectively activates,” as used herein, refers to the ability of a ligand, e.g., peptide, to activate a receptor, e.g., preferentially interact with, in the presence of other different receptors. In certain embodiments, a ligand can selectively activate two different GPCRs in the presence of other receptors.
The term “reportable component,” as used herein, indicates a component capable of detection in one or more systems and/or environments.
The terms “detect” or “detection,” as used herein, indicates the determination of the existence and/or presence of a target in a limited portion of space, including but not limited to a sample, a reaction mixture, a molecular complex and a substrate. The “detect” or “detection” as used herein can comprise determination of chemical and/or biological properties of the target, including but not limited to ability to interact, and in particular bind, other compounds, ability to activate another compound and additional properties identifiable by a skilled person upon reading of the present disclosure. The detection can be quantitative or qualitative. A detection is “quantitative” when it refers, relates to, or involves the measurement of quantity or amount of the target or signal (also referred as quantitation), which includes but is not limited to any analysis designed to determine the amounts or proportions of the target or signal. A detection is “qualitative” when it refers, relates to, or involves identification of a quality or kind of the target or signal in terms of relative abundance to another target or signal, which is not quantified.
The term “derived” or “derive” is used herein to mean to obtain from a specified source.
The term “daisy-chaining,” as used herein, refers to a method of providing a network having greater complexity than a point-to-point network, wherein adding more nodes (e.g., more than two linked cells) is achieved by linking each additional node (e.g., cell) one to another. Accordingly, in a “daisy chain” type of network comprising multiple nodes (e.g., multiple different types of cells), a signal is passed through the network from one node (e.g., cell) to another in series in a stepwise manner, from a first terminal node (e.g., cell) to a second terminal node (e.g., cell) through one or more intermediary nodes (e.g., cells). This can be contrasted, for example, to a “bus” type of network wherein nodes can be connected to each other through a singular common link. A “daisy chain” network topology can be a daisy chain linear network topology or a daisy chain ring network topology. In certain embodiments, a daisy chain linear network topology or a daisy chain ring network topology can further comprise one or more branches that extend from one or more intermediary nodes (e.g., cells) in the network topology, also referred to herein as a “branched” network topology. In certain embodiments, the “branched” network has a “star” topology or a “ring” topology. Non-limiting examples of daisy chain network configurations are shown in
A “star” network topology, as used herein, refers to a network that includes branches, e.g., a cell or cells, that can be connected to each other through a singular common link, e.g., cell.
A “mesh” network topology, as used herein, refers to a network where all the cells with the network are connected to as many other cells as possible.
A “ring” network topology, as used herein, refers to a network that comprises cells that are connected in a manner where the last cell in the chain is connected back to the first cell in the chain. Non-limiting examples of ring network configurations are shown in
A “bus” type of network topology, as used herein, and as referenced above, can refer to a network of cells comprising cells that can be connected to each other through a singular common cell. A non-limiting example of a bus type of network is shown in
A “branched” type of network topology, as used herein, and as referenced above, can refer to a network of cells that include one or more branches that extend from one or more intermediary cells. Non-limiting examples of branched type network configurations are shown in
The present disclosure provides GPCRs and ligands for an intercellular communication language between two or more cells, e.g., of the phylum Ascomycota. In certain embodiments, the intercellular signaling system utilizes expression vectors to achieve expression of GPCRs and cognate ligands in fungal cells, e.g., yeast cells (e.g., S. cerevisiae).
GPCRs
G protein-coupled receptors (GPCRs), also known as seven-transmembrane domain receptors, 7TM receptors, heptahelical receptors, serpentine receptor and G protein-linked receptors (GPLR), constitute a large protein family of receptors that detect molecules outside the cell and activate internal signal transduction pathways and, ultimately, cellular responses. G protein-coupled receptors are found only in eukaryotes, such as yeast and animals. The ligands that bind and activate these receptors include light-sensitive compounds, odors, pheromones, hormones, toxins, and neurotransmitters, and vary in size from small molecules to peptides to large proteins. When a ligand binds to the GPCR it causes a conformational change in the GPCR, allowing it to act as a guanine nucleotide exchange factor (GEF). The GPCR can then activate an associated G protein by exchanging the GDP bound to the G protein for a GTP. The G protein's a subunit, together with the bound GTP, can then dissociate from the β and γ subunits to further affect intracellular signaling proteins or target functional proteins directly depending on the a subunit type (Gαs, Gαi/o, Gαq/11, Gα12/13) (see, e.g.,
The present disclosure provides GPCRs for use in the intercellular signaling systems of the present disclosure. In certain embodiments, the GPCRs for use in the present disclosure can be identified and/or derived from any eukaryotic organism, e.g., an animal, plant, fungus and/or protozoan. In certain embodiments, GPCRs for use in the present disclosure can be identified and/or derived from mammalian cells. In certain embodiments, GPCRs for use in the present disclosure can be identified and/or derived from plant cells. In certain embodiments, GPCRs for use in the present disclosure can be identified and/or derived from fungal cells, e.g., a fungal GPCR. For example, but not by way of limitation, GPCRs for use in the present disclosure can be identified and/or derived from Metozoans, Unicellular Holozoa and Amoebazoa. Additional non-limiting examples of organisms that can be used to identify and/or derive GPCRs for use in the present disclosure is provided in FIG. 2 of Mendoza et al., Genome Biol. Evol. 6(3):606-619 (2014), which is incorporated herein in its entirety.
In certain embodiments, a GPCR of the present disclosure can be identified and/or derived from the genome of a species of the phylum Ascomycota. Ascomycota is a division or phylum of the kingdom Fungi that, together with the Basidiomycota, form the subkingdom Dikarya. Its members are commonly known as the sac fungi or ascomycetes. Ascomycota is the largest phylum of Fungi, with over 64,000 species. A defining feature of this fungal group is the ascus, a microscopic sexual structure in which nonmotile spores, called ascospores, are formed. Ascomycetes can be identified and classified based on morphological or physiological similarities, and by phylogenetic analyses of DNA sequences (e.g., as described in Lutzoni F. et al. (2004), American Journal of Botany 91 (10): 1446-80 and James TY. et al. (2006), Nature 443 (7113): 818-22). Non-limiting examples of such species include Saccharomyces cerevisiae, Saccharomyces castellii, Vanderwaltozyma polyspora, Torulaspora delbrueckii, Saccharomyces kluyveri, Kluyveromyces lactis, Zygosaccharomyces rouxii, Zygosaccharomyces bailii, Candida glabrata, Ashbya gossypii, Scheffersomyces stipites, Komagataella (Pichia) pastoris, Candida (Pichia) guilliermondii, Candida parapsilosis, Candida auris, Yarrowia lipolytica, Candida (Clavispora) lusitaniae, Candida albicans, Candida tropicalis, Candida tenuis, Lodderomyces elongisporous, Geotrichum candidum, Baudoinia compniacensis, Schizosaccharomyces octosporus, Tuber melanosporum, Aspergillus oryzae, Schizosaccharomyces pombe, Aspergillus (Neosartorya) fischeri, Pseudogymnoascus destructans, Schizosaccharomyces japonicus, Paracoccidioides brasiliensis, Mycosphaerella graminicola, Penicillium chrysogenum, Aspergillus nidulans, Phaeosphaeria nodorum, Hypocrea jecorina, Botrytis cinereal, Beauvaria bassiana, Neurospora crassa, Sporothrix scheckii, Magnaporthe oryzea, Dactylellina haptotyla, Fusarium graminearum, and Capronia coronate. See also Table 3, which provides a list of potential species from which GPCRs can be obtained and/or derived. In certain embodiments, the GPCR is identified and/or derived from the genome of Saccharomyces cerevisiae.
In certain embodiments, the GPCR or portion thereof for use in the present disclosure is a seven-transmembrane domain receptor that can be selectively activated by interaction with a ligand. In certain embodiments, the GPCR or portion thereof for use in the present disclosure can interact with and activate G proteins.
In certain embodiments, the GPCR or a portion thereof for use in the present disclosure comprises an amino acid sequence of any one of SEQ ID NOs: 117-161, or conservative substitutions thereof or a homolog thereof (see Table 9). In certain embodiments, the GPCR or portion thereof comprises an amino acid sequence that is at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% homologous to a sequence comprising any one of SEQ ID NOs: 117-161.
In certain embodiments, the GPCR or a portion thereof for use in the present disclosure comprises a nucleotide sequence of any of SEQ ID NOs: 168-211, or conservative substitutions thereof or a homolog thereof (see Table 5). In certain embodiments, the GPCR or portion thereof comprises a nucleotide sequence that is at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% homologous to a sequence comprising any one of SEQ ID NOs: 168-211.
In certain embodiments, the GPCR or a portion thereof for use in the present disclosure comprises an amino acid sequence of any one of the GPCRs disclosed in Table 4 and Table 6 of U.S. Publication No. 2017/0336407, the content of which is incorporated in its entirety by reference herein. For example, but not by way of limitation, the GPCR or portion thereof comprises an amino acid sequence that is at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% homologous to an amino acid sequence disclosed in Table 4 and Table 6 of U.S. Publication No. 2017/0336407.
In certain embodiments, the GPCR or a portion thereof for use in the present disclosure comprises an amino acid sequence of any one of the GPCRs listed in Table 11. In certain embodiments, the GPCR or portion thereof comprises an amino acid sequence that is at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% homologous to an amino acid sequence of any one of the GPCRs listed in Table 11.
Acidomyces richmondensis BFW
Acremonium_chrysogenum_strain_ATCC 11550
Ajellomyces capsulatus strain G186AR
Ajellomyces_capsulatus_strain_H143
Ajellomyces_capsulatus_strain_NAm1
Ajellomyces_dermatitidis_strain_SLH14081
Alternaria alternata
Arthrobotrys_oligospora_strain_ATCC_24927
Arthroderma_benhamiae_strain_ATCC_MYA-4681
Arthroderma_gypseum_strain_ATCC_MYA-4604
Arthroderma_otae_strain_ATCC_MYA-4605
Aschersonia aleyrodis RCEF 2490
Ascosphaera apis ARSEF 7405
Ashbya_aceri
Ashbya_gossypii_strain_ATCC_10895
Aspergillus calidoustus
Aspergillus clavatus strain ATCC 1007
Aspergillus flavus strain ATCC 200026
Aspergillus_fumigatus_Z5
Aspergillus_kawachii_strain_NBRC_4308
Aspergillus lentulus
Aspergillus luchuensis
Aspergillus niger
Aspergillus niger strain CBS 51388
Aspergillus nomius NRRL 13137
Aspergillus ochraceoroseus
Aspergillus_oryzae_strain_3042
Aspergillus_parasiticus_strain_ATCC_56775
Aspergillus rambellii
Aspergillus ruber CBS 135680
Aspergillus terreus strain NIH 2624
Aspergillus_udagawae
Aureobasidium_melanogenum_CBS_110374
Aureobasidium namibiae CBS 14797
Aureobasidium pullulans EXF-150
Aureobasidium subglaciale EXF-2481
Baudoinia_compniacensis_strain_UAMH_10762
Beauveria_bassiana_D1-5
Beauveria bassiana strain ARSEF 2860
Bionectria ochroleuca
Bipolaris oryzae ATCC 44560
Bipolaris_victoriae_FI3
Bipolaris_zeicola_26-R-13
Blastobotrys adeninivorans
Blumeria_graminis_f_sp_hordei_strain_DH14
Botryosphaeria parva strain UCR-NP2
Botryotinia fuckeliana strain T4
Byssochlamys spectabilis strain No 5
Candida albicans P75010
Candida_albicans_strain_SC5314
Candida_albicans_strain_WO-1
Candida auris
Candida dubliniensis strain CD36
Candida glabrata
Candida_glabrata_strain_ATCC_2001
Candida_maltosa_strain_Xu316
Candida orthopsilosis strain 90-125
Candida parapsilosis strain CDC 317
Candida tenuis strain ATCC 10573
Candida_tropicalis_strain_ATCC_MYA-3404
Capronia_epimyces_CBS_60696
Capronia semi-immersa
Ceratocystis fimbriata f sp platani
Chaetomium_globosum_strain_ATCC_6205
Chaetomium_thermophilum_strain_DSM_1495
Cladophialophora_bantiana_CBS_17352
Cladophialophora carrionii CBS 16054
Cladophialophora_psammophila_CBS_110553
Cladophialophora yegresii CBS 114405
Claviceps purpurea strain 201
Clavispora_lusitaniae_strain_ATCC_42720
Coccidioides posadasii strain C735
Cochliobolus_heterostrophus_strain_C5
Cochliobolus_sativus_strain_ND90Pr
Colletotrichum fioriniae PJ7
Colletotrichum_gloeosporioides_strain_Cg-14
Colletotrichum_gloeosporioides_strain_Nara gc5
Coniosporium_apollinis_strain_CBS_100218
Cordyceps_brongniartii_RCEF_3172
Cordyceps confragosa
Cordyceps confragosa RCEF 1005
Cordyceps militaris strain CM01
Cyberlindnera_fabianii
Cyberlindnera_jadinii
Cyphellophora europaea CBS 101466
Debaryomyces fabryi
Debaryomyces_hansenii_strain_ATCC_36239
Diaporthe_ampelina
Didymella_rabiei
Diplodia seriata
Dothistroma septosporum strain NZE10
Drechmeria coniospora
Drechslerella stenobrocha 248
Emericella nidulans
Emmonsia crescens UAMH 3008
Emmonsia_parva_UAMH_139
Endocarpon_pusilium_strain_Z07020
Eremothecium cymbalariae
Eremothecium_cymbalariae_strain_CBS_27075
Eremothecium sinecaudum
Escovopsis_weberi
Eutypa_lata_strain_UCR-EL1
Exophiala aquamarina CBS 119918
Exophiala_dermatitidis_strain_ATCC_34100
Exophiala mesophila
Exophiala_oligosperma
Exophiala_sideris
Exophiala spinifera
Exophiala xenobiotica
Fonsecaea erecta
Fonsecaea_monophora
Fonsecaea_multimorphosa
Fonsecaea multimorphosa CBS 102226
Fonsecaea nubica
Fonsecaea pedrosoi CBS 27137
Fusarium langsethiae
Fusarium_oxysporum_f_sp_cubense_strain race 1
Fusarium_oxysporum_f_sp_cubense_strain race 4
Fusarium_oxysporum_f_sp_cubense_trop-
Fusarium_oxysporum_f_sp_lycopersici_strain_4287
Fusarium_oxysporum_f_sp_melonis_26406
Fusarium oxysporum f sp pisi HDV247
Fusarium_oxysporum_f_sp_raphani_54005
Fusarium_oxysporum_Fo47
Fusarium_oxysporum_FOSC_3-a
Fusarium oxysporum strain Fo5176
Fusarium_pseudograminearum_strain_CS3096
Gaeumannomyces_graminis_var_tritici_strain R3-111a-1
Geotrichum_candidum
Gibberella_fujikuroi
Gibberella fujikuroi strain CBS 19534
Gibberella moniliformis strain M3125
Gibberella zeae strain PH-1
Glarea_lozoyensis_strain_ATCC_20868
Grosmannia_clavigera_strain_kw1407
Hanseniaspora uvarum DSM 2768
Hypocrea_atroviridis_strain_ATCC_20476
Hypocrea jecorina
Hypocrea jecorina strain ATCC 56765
Hypocrea jecorina strain QM6a
Hypocrea virens strain Gv29-8
Hypocrella_siamensis
Isaria_fumosorosea_ARSEF_2679
Kazachstania_africana_strain_ATCC_22294
Kazachstania_naganishii_strain_ATCC_MYA-139
Kluyveromyces dobzhanskii CBS 2104
Kluyveromyces_lactis_strain_ATCC_8585
Kluyveromyces_marxianus_DMKU3-1042
Komagataella pastoris strain GS115
Kuraishia capsulata CBS 1993
Lachancea kluyveri
Lachancea_lanzarotensis
Lachancea_quebecensis
Lachancea_thermotolerans_strain_ATCC 56472
Leptosphaeria maculans strain JN3
Lodderomyces_elongisporus_strain_ATCC 11503
Macrophomina_phaseolina_strain_MS6
Madurella_mycetomatis
Magnaporthe oryzae strain 70-15
Magnaporthe oryzae strain Y34
Magnaporthiopsis_poae_strain_ATCC_64411
Marssonina_brunnea_f_sp_multigermtubi strain MB m1
Metarhizium acridum strain CQMa 102
Metarhizium album ARSEF 1941
Metarhizium_anisopliae_ARSEF_549
Metarhizium_anisopliae_BRIP_53293
Metarhizium brunneum ARSEF 3297
Metarhizium guizhouense ARSEF 977
Metarhizium majus ARSEF 297
Metarhizium_rileyi_RCEF_4871
Metarhizium_robertsii
Metarhizium robertsii strain ARSEF 23
Meyerozyma_guilliermondii_strain_ATCC 6260
Naumovozyma_castellii_strain_ATCC_76901
Naumovozyma_dairenensis_strain_ATCC_10597
Nectria_haematococca_strain_77-13-4
Neonectria ditissima
Neosartorya fischeri strain ATCC 1020
Neosartorya fumigata strain CEA10
Neurospora_africana
Neurospora_calospora
Neurospora cerealis
Neurospora crassa
Neurospora crassa strain ATCC 24698
Neurospora galapagosensis
Neurospora hapsidophora
Neurospora intermedia
Neurospora_kobi
Neurospora_lineolata
Neurospora novoguineensis
Neurospora pannonica
Neurospora retispora
Neurospora_santi-florii
Neurospora_sitophila
Neurospora sp FGSC 8780
Neurospora sp FGSC 8815
Neurospora sp FGSC 8817
Neurospora_sp_FGSC_8827
Neurospora_sp_FGSC_8842
Neurospora sp FGSC 8853
Neurospora sublineolata
Neurospora terricola
Neurospora_tetrasperma
Neurospora_uniporata
Ogataea_parapolymorpha_strain_ATCC_26012
Oidiodendron maius Zn
Ophiocordyceps sinensis strain Co18
Ophiocordyceps unilateralis
Ophiostoma_piceae_strain_UAMH_11346
Paracoccidioides_brasiliensis_strain_Pb03
Paracoccidioides_brasiliensis_strain_Pb18
Paracoccidioides_lutzii_strain_ATCC_MYA-826
Paraphaeosphaeria sporulosa
Penicillium brasilianum
Penicillium camemberti FM 013
Penicillium_chrysogenum
Penicillium_digitatum_strain_PHI26
Penicillium expansum
Penicillium freii
Penicillium italicum
Penicillium_nordicum
Penicillium_oxalicum_strain_114-2
Penicillium patulum
Penicillium roqueforti strain FM164
Pestalotiopsis fici W106-1
Phaeomoniella_chlamydospora
Phaeosphaeria_nodorum_strain_SN15
Pichia kudriavzevii
Pichia_sorbitophila_strain_ATCC_MYA-4447
Pichia_sorbitophila_strain_ATCC_MYA-4447
Pneumocystis carinii
Pneumocystis carinii B80
Pneumocystis jiroveci strain SE8
Pneumocystis_jirovecii_RU7
Pneumocystis_murina_strain_B123
Pochonia chlamydosporia 170
Podospora anserina strain S
Pseudocercospora_fijiensis_strain_CIRAD86
Pseudogymnoascus_destructans
Pseudogymnoascus_destructans_strain_ATCC_MYA-4855
Pseudogymnoascus sp VKM F-103
Pseudogymnoascus sp VKM F-3557
Pseudogymnoascus sp VKM F-3775
Pseudogymnoascus_sp_VKM_F-3808
Pseudogymnoascus_sp_VKM_F-4246
Pseudogymnoascus_sp_VKM_F-4281 FW-2241
Pseudogymnoascus_sp_VKM_F-4513 FW-928
Pseudogymnoascus_sp_VKM_F-4515 FW-2607
Pseudogymnoascus_sp_VKM_F-4516_FW-969
Pseudogymnoascus_sp_VKM_F-4517 FW-2822
Pseudogymnoascus_sp_VKM_F-4518 FW-2643
Pseudogymnoascus_sp_VKM_F-4519 FW-2642
Pseudogymnoascus_sp_VKM_F-4520 FW-2644
Purpureocillium lilacinum
Pyrenochaeta sp DS3sAY3a
Pyrenophora teres f teres strain 0-1
Pyrenophora_tritici-repentis_strain_Pt-1C-BFP
Pyronema_omphalodes_strain_CBS_100304
Rasamsonia emersonii CBS 39364
Rhinocladiella mackenziei CBS 65093
Saccharomyces arboricola strain H-6
Saccharomyces_bayanus
Saccharomyces_cerevisiae_strain_ATCC_204508
Saccharomyces_cerevisiae_strain_AWRI796
Saccharomyces_cerevisiae_strain_FostersO
Saccharomyces_cerevisiae_strain_RM11-1a
Saccharomyces_cerevisiae_strain_YJM789
Saccharomyces_cerevisiae_×_Saccha-
romyces_kudriavzevii_strain_VIN7
Saccharomyces paradoxus
Saccharomyces pastorianus
Saccharomyces sp ‘boulardii’
Saitoella_complicata_NRRL_Y-17804
Scedosporium_apiospermum
Scheffersomyces_stipitis_strain_ATCC_58785
Schizosaccharomyces_cryophilus_strain_OY26
Schizosaccharomyces_japonicus_strain_yFS275
Schizosaccharomyces_octosporus_strain_yFS286
Schizosaccharomyces pombe strain 972
Sclerotinia borealis F-4157
Sclerotinia_sclerotiorum_strain_ATCC_18683
Setosphaeria_turcica_strain_28A
Sordaria_macrospora_strain_ATCC_MYA-333
Spathaspora_passalidarum_strain_NRRLY-27907
Sphaerulina musiva strain SO2202
Sporothrix_brasiliensis_5110
Sporothrix_insectorum_RCEF_264
Sporothrix schenckii
Sporothrix schenckii 1099-18
Sporothrix_schenckii_strain_ATCC_58251
Stachybotrys_chartarum_IBT_40288
Stachybotrys_chartarum_IBT_7711
Stachybotrys chlorohalonata IBT 40285
Stagonospora sp SRC1lsM3a
Stemphylium lycopersici
Sugiyamaella
—
lignohabitans
Talaromyces
—
islandicus
Talaromyces marneffei PM1
Talaromyces_marneffei_strain_ATCC_18224
Talaromyces_stipitatus_strain_ATCC_10500
Tetrapisispora_blattae_strain_ATCC_34711
Tetrapisispora_phaffii_strain_ATCC_24235
Togninia minima strain UCR-PA7
Tolypocladium_ophioglossoides_CBS_100239
Torrubiella_hemipterigena
Torulaspora_delbrueckii_strain_ATCC_10662
Trichoderma gamsii
Trichoderma harzianum
Trichophyton_equinum_strain_ATCC_MYA-4606
Trichophyton_interdigitale_MR816
Trichophyton rubrum
Trichophyton rubrum CBS 28886
Trichophyton_verrucosum_strain_HKI_0517
Trichophyton_violaceum
Tuber_melanosporum_strain_Mel28
Uncinocarpus_reesii_strain_UAMH_1704
Uncinula necator
Ustilaginoidea virens
Vanderwaltozyma_polyspora_strain_ATCC_22028
Vanderwaltozyma_polyspora_strain_ATCC_22028
Verruconis gallopava
Verticillium alfalfae strain VaMs102
Verticillium dahliae strain VdLs17
Verticillium longisporum
Wickerhamomyces_ciferrii_strain_F-60-10
Xylona heveae TC161
Yarrowia_lipolytica_strain_CLIB_122
Zygosaccharomyces_bailii_ISA1307
Zygosaccharomyces_bailii_strain_CLIB_213
Zygosaccharomyces_rouxii_strain_ATCC 2623
Zymoseptoria brevis
Zymoseptoria_tritici_strain_CBS_115943
In certain embodiments, the GPCR or a portion thereof for use in the present disclosure comprises an amino acid sequence or a nucleotide sequence that has greater than about 15% homology to any one of the GPCRs disclosed herein and further comprises a characteristic seven transmembrane helix domain. For example, but not by way of limitation, the GPCR or a portion thereof comprises an amino acid sequence that has greater than about 15% homology to an amino acid sequence comprising any one of SEQ ID NOs: 117-161 or an amino acid sequence of any one of the GPCRs listed in Table 11 and further comprises a characteristic seven transmembrane helix domain. In certain embodiments, the GPCR or a portion thereof comprises a nucleotide sequence that has greater than about 15% homology to a nucleotide sequence comprising any one of SEQ ID NOs: 168-211 and further comprises a characteristic seven transmembrane helix domain. In certain embodiments, the GPCR or a portion thereof for use in the present disclosure comprises an amino acid sequence that has greater than about 15%, greater than about 20%, greater than about 25%, greater than about 30%, greater than about 35%, greater than about 40%, greater than about 45%, greater than about 50%, greater than about 55%, greater than about 60%, greater than about 65%, greater than about 70%, greater than about 75%, greater than about 80%, greater than about 85%, greater than about 90%, greater than about 91%, greater than about 92%, greater than about 93%, greater than about 94%, greater than about 95%, greater than about 96%, greater than about 97%, greater than about 98% or greater than about 99% homology to any one of the GPCRs disclosed herein and further comprises a characteristic seven transmembrane helix domain. For example, but not by way of limitation, the GPCR or a portion thereof comprises an amino acid greater than about 15% homology, greater than about 20%, greater than about 25%, greater than about 30%, greater than about 35%, greater than about 40%, greater than about 45%, greater than about 50%, greater than about 55%, greater than about 60%, greater than about 65%, greater than about 70%, greater than about 75%, greater than about 80%, greater than about 85%, greater than about 90%, greater than about 91%, greater than about 92%, greater than about 93%, greater than about 94%, greater than about 95%, greater than about 96%, greater than about 97%, greater than about 98% or greater than about 99% homology to an amino acid sequence comprising any one of SEQ ID NOs: 117-161 or an amino acid sequence of any one of the GPCRs listed in Table 11 and further comprises a characteristic seven transmembrane helix domain.
In certain embodiments, the GPCR is a variant of the yeast Ste2 receptor or Ste3 receptor. The mating factor receptors Ste2 and Ste3 are integral membrane proteins that can be involved in the response to mating factors on the cell membrane. The Ste2 subfamily represents the alpha-factor peptide pheromone receptor encoded by the Ste2 gene, and the Ste3 subfamily represents the a-factor peptide pheromone receptor encoded by the Ste3 gene, which are required for peptide pheromone sensing and mating in haploid cells of the yeast Saccharomyces cerevisiae. The Ste2-encoded and Ste3-encoded seven-transmembrane domain receptors are the two major subfamily members of the class D GPCRs. Ste2 and Ste3 GPCRs sense the peptide mating pheromones, alpha-factor and a-factor, which activate a GPCR on the surface of the opposite yeast-mating haploid-types (MATa and MAT-alpha), respectively. In certain embodiments, the Ste2 receptor or Ste3 receptor is modified so that it binds to a ligand disclosed herein rather than a yeast pheromone. For example, but not by way of limitation, the GPCR or portion thereof is a polypeptide that is at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% homologous to the native yeast Ste2 or yeast Ste3 receptor.
In certain embodiments, a homolog of a nucleotide sequence can be a polynucleotide having changes in one or more nucleotide bases that can result in substitution of one or more amino acids, but do not affect the functional properties of the polypeptide or protein encoded by the nucleotide sequence. Homologs can also include polynucleotides having modifications such as deletion, addition or insertion of nucleotides that do not substantially affect the functional properties of the resulting polynucleotide or transcript. Alterations in a polynucleotide that result in the production of a chemically equivalent amino acid at a given site, but do not affect the functional properties of the encoded polypeptide, are well known in the art.
In certain embodiments, a homolog of a peptide, polypeptide or protein can be a peptide, polypeptide or protein having changes in one or more amino acids but do not affect the functional properties of the peptide, polypeptide or protein. Alterations in a peptide, polypeptide or protein that do not affect the functional properties of the peptide, polypeptide or protein, are well known in the art, e.g., conservative substitutions. It is therefore understood that the disclosure encompasses more than the specific exemplary polynucleotide or amino acid sequences and includes functional equivalents thereof.
Conservative substitutions are shown in Table 1, under the heading of “conservative substitutions.” More substantial changes are also provided in Table 1 under the heading of “exemplary substitutions,” and as further described below in reference to amino acid side chain classes.
Amino acids can be grouped according to common side-chain properties:
(1) hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile;
(2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln;
(3) acidic: Asp, Glu;
(4) basic: His, Lys, Arg;
(5) residues that influence chain orientation: Gly, Pro;
(6) aromatic: Trp, Tyr, Phe.
Non-conservative substitutions will entail exchanging a member of one of these classes for a member of another class.
In certain embodiments, GPCRs for use in the present disclosure are identified by searching a protein and/or genomic database and/or literature for a protein and/or a gene with homology to the S. cerevisiae Ste2 receptor and/or Ste3 receptor, e.g., the identified GPCR has an amino acid sequence that is at least about 15%, e.g., at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99%, homologous to the S. cerevisiae Ste2 receptor and/or Ste3 receptor.
In certain embodiments, GPCRs for use in the present disclosure are identified by searching a protein and/or genomic database and/or literature for a protein and/or a gene with homology to any of the GPCRs disclosed herein. For example, but not by way of limitation, the identified GPCR can have an amino acid sequence that is at least about 15% homologous, e.g., at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99%, homologous to a GPCR comprising an amino acid sequence of any one of SEQ ID NOs: 117-161, a GPCR provided in Table 11 and/or a GPCR encoded by a nucleotide sequence comprising any one of SEQ ID NOs: 168-211.
In certain embodiments, the protein and/or genomic database is selected from the group consisting of NCBI, Genbank, Interpro, PFAM, Uniprot and a combination thereof.
GPCR Ligands
The present disclosure further provides ligands (referred to herein as a “GPCR ligand”) configured to interact with (directly and/or indirectly) and activate a GPCR disclosed herein. For example, but not by way of limitation, a GPCR ligand of the present disclosure selectively interacts with a single GPCR allowing activation of the single GPCR in the presence of two or more GPCRs, e.g., where each distinct GPCR is expressed by a separate cell or in the same cell.
In certain embodiments, the ligand can be any molecule that is configured to interact with and activate a GPCR disclosed herein or a GPCR identified by the methods disclosed herein, e.g., by genome mining. For example, but not by way of limitation, the ligand can be a peptide, a protein or portion thereof and/or a small molecule (e.g., nucleotides, lipids, chemicals, toxins, photons, electrical signals and compounds). Non-limiting examples of small molecules include pinene, serotonin and hydroxystrictosidine. See, e.g., Ehrenworth et al., Biochemistry 56(41):5471-5475 (2017), which is incorporated herein in its entirety. Additional examples of ligands for use in the present disclosure is provided in Tables 1 and 2 of Muratspahic et al., Nature-Derived Peptides: A Growing Niche for GPCR Ligand Discovery, Trends in Pharmacological Sciences (2019), in Supplementary Table 3 of Sriram and Insel, GPCRs as targets for approved drugs: How many targets and how many drugs?, Molecular Pharmacology, mol.117.111062 (2018) and in Tables 2, 3 and 5 of U.S. Publication No. 2017/0336407, the contents of which are incorporated herein in their entireties.
In certain embodiments, the ligand is a peptide ligand (referred to herein as a “GPCR peptide ligand”). In certain embodiments, the peptide ligand is secretable (referred to herein as a “secretable GPCR peptide ligand”). For example, but not by way of limitation, the peptide ligand can be expressed intracellularly in a cell and subsequently transported to the plasma membrane of the cell and secreted to the exterior of the cell, e.g., outside the plasma membrane of the cell. In certain embodiments, the peptide is secretable because the peptide is coupled to a secretion signal sequence. In certain embodiments, secretion can be performed using the conserved secretory pathway in yeast.
In certain embodiments, the GPCR peptide ligand, e.g., secretable GPCR peptide ligand, comprises a peptide identified and/or derived from the genome of a species of the phylum Ascomycota. Non-limiting examples of such species include Saccharomyces cerevisiae, Saccharomyces castellii, Vanderwaltozyma polyspora, Torulaspora delbrueckii, Saccharomyces kluyveri, Kluyveromyces lactis, Zygosaccharomyces rouxii, Zygosaccharomyces bailii, Candida glabrata, Ashbya gossypii, Scheffersomyces stipites, Komagataella (Pichia) pastoris, Candida (Pichia) guilliermondii, Candida parapsilosis, Candida auris, Yarrowia lipolytica, Candida (Clavispora) lusitaniae, Candida albicans, Candida tropicalis, Candida tenuis, Lodderomyces elongisporous, Geotrichum candidum, Baudoinia compniacensis, Schizosaccharomyces octosporus, Tuber melanosporum, Aspergillus oryzae, Schizosaccharomyces pombe, Aspergillus (Neosartorya) fischeri, Pseudogymnoascus destructans, Schizosaccharomyces japonicus, Paracoccidioides brasiliensis, Mycosphaerella graminicola, Penicillium chrysogenum, Aspergillus nidulans, Phaeosphaeria nodorum, Hypocrea jecorina, Botrytis cinereal, Beauvaria bassiana, Neurospora crassa, Sporothrix scheckii, Magnaporthe oryzea, Dactylellina haptotyla, Fusarium graminearum, and Capronia coronate.
In certain embodiments, the GPCR peptide ligand, e.g., secretable GPCR peptide ligand, can be composed of about 3-50 amino acid residues. In certain embodiments, the 3-50 amino acid residues can be continuous within a larger polypeptide or protein, or can be a group of 3-50 residues that are discontinuous in a primary sequence of a larger polypeptide or protein but that are spatially near in three-dimensional space. In certain embodiments, the GPCR peptide ligand, e.g., secretable GPCR peptide ligand, can stretch over the complete length of a polypeptide or protein, the GPCR peptide ligand can be part of a peptide, the GPCR peptide ligand can be part of a full protein or polypeptide and can be released from that protein or polypeptide by proteolytic treatment or can remain part of the protein or polypeptide. For example, but not by way of limitation, the GPCR peptide ligand, e.g., secretable GPCR peptide ligand, can be expressed in a cell as part of a longer peptide, e.g., a precursor peptide, that is subsequently processed by proteolytic cleavage to obtain the mature form of the GPCR peptide ligand (see Table 4).
In certain embodiments, the GPCR peptide ligand, e.g., the mature GPCR peptide ligand, can have a length of 3 residues or more, a length of 4 residues or more, a length of 5 residues or more, 6 residues or more, 7, residues or more, 8 residues or more, 9 residues or more, 10 residues or more, 11 residues or more, 12 residues or more, 13 residues or more, 14 residues or more, 15 residues or more, 16 residues or more, 17 residues or more, 18 residues or more, 19 residues or more, 20 residues or more, 21 residues or more, 22 residues or more, 23 residues or more, 24 residues or more, 25 residues or more, 26 residues or more, 27 residues or more, 28 residues or more, 29 residues or more, 30 residues or more, 31 residues or more, 32 residues or more, 33 residues or more, 34 residues or more, 35 residues or more, 36 residues or more, 37 residues or more, 38 residues or more, 39 residues or more, 40 residues or more, 41 residues or more, 42 residues or more, 43 residues or more, 44 residues or more, 45 residues or more, 46 residues or more, 47 residues or more, 48 residues or more, 49 residues or more or 50 residues or more. In certain embodiments, the GPCR peptide ligand has a length of 3-50 residues, 5-50 residues, 3-45 residues, 5-45 residues, 3-40 residues, 5-40 residues, 3-35 residues, 5-35 residues, 3-30 residues, 5-30 residues, 3-25 residues, 5-25 residues, 3-20 residues, 5-20 residues, 3-15 residues, 5-15 residues, 3-10 residues, 3-10 residues, 5-10 residues, 10-15 residues, 15-20 residues, 20-25 residues, 25-30 residues, 30-35 residues, 35-40 residues, 40-45 residues or 45-50 residues. In certain embodiments, the secretable GPCR peptide ligand has a length of about 5 to about 30 residues.
In certain embodiments, the GPCR peptide ligand has a length of 9 residues. In certain embodiments, the GPCR peptide ligand has a length of 10 residues. In certain embodiments, the GPCR peptide ligand has a length of 11 residues. In certain embodiments, the GPCR peptide ligand has a length of 12 residues. In certain embodiments, the GPCR peptide ligand has a length of 13 residues. In certain embodiments, the GPCR peptide ligand has a length of 14 residues. In certain embodiments, the GPCR peptide ligand has a length of 15 residues. In certain embodiments, the GPCR peptide ligand has a length of 16 residues. In certain embodiments, the GPCR peptide ligand has a length of 17 residues. In certain embodiments, the GPCR peptide ligand has a length of 18 residues. In certain embodiments, the GPCR peptide ligand has a length of 19 residues. In certain embodiments, the GPCR peptide ligand has a length of 20 residues. In certain embodiments, the GPCR peptide ligand has a length of 21 residues. In certain embodiments, the GPCR peptide ligand has a length of 22 residues. In certain embodiments, the GPCR peptide ligand has a length of 23 residues. In certain embodiments, the GPCR peptide ligand has a length of 24 residues. In certain embodiments, the GPCR peptide ligand has a length of 25 residues. In certain embodiments, the GPCR peptide ligand has a length of 26 residues. In certain embodiments, the GPCR peptide ligand has a length of 27 residues. In certain embodiments, the GPCR peptide ligand has a length of 28 residues. In certain embodiments, the GPCR peptide ligand has a length of 29 residues. In certain embodiments, the GPCR peptide ligand has a length of 30 residues.
In certain embodiments, the GPCR peptide ligand, e.g., secretable GPCR peptide ligand, or portion thereof can comprise an amino acid sequence of any one of SEQ ID NOs: 1-72, or conservative substitutions thereof or a homolog thereof (see Table 3). In certain embodiments, the GPCR peptide ligand, e.g., secretable GPCR peptide ligand, comprises an amino acid sequence that is at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% homologous to a sequence comprising any one of SEQ ID NOs: 1-72.
In certain embodiments, the GPCR peptide ligand, e.g., secretable GPCR peptide ligand, or portion thereof comprises an amino acid sequence of any one of SEQ ID NOs: 73-116, or conservative substitutions thereof or a homolog thereof (see Table 4). In certain embodiments, the GPCR peptide ligand or portion thereof comprises an amino acid sequence that is at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% homologous to sequence comprising any one of SEQ ID NOs: 73-116.
In certain embodiments, the GPCR peptide ligand, e.g., secretable GPCR peptide ligand, or portion thereof comprises a nucleotide sequence of any one of SEQ ID NOs: 215-230, or conservative substitutions thereof or a homolog thereof (see Table 7). In certain embodiments, the GPCR peptide ligand, e.g., secretable GPCR peptide ligand, or portion thereof comprises a nucleotide sequence that is at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% homologous to a nucleotide sequence comprising any one of SEQ ID NOs: 215-230.
In certain embodiments, the GPCR peptide ligand can comprise a peptide disclosed in Table 12 or conservative substitutions thereof or a homolog thereof. In certain embodiments, the GPCR peptide ligand, e.g., secretable GPCR peptide ligand, or portion thereof comprises a nucleotide sequence that is at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% homologous to a sequence disclosed in Table 12.
In certain embodiments, the GPCR peptide ligand can comprise a peptide disclosed in Tables 2, 3 and 5 of U.S. Publication No. 2017/0336407. For example, but not by way of limitation, the GPCR peptide ligand or portion thereof comprises an amino acid sequence that is at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% homologous to an amino acid sequence disclosed in Tables 2, 3 and 5 of U.S. Publication No. 2017/0336407.
In certain embodiments, the GPCR peptide ligand for use in the present disclosure comprises an amino acid sequence or nucleotide sequence that has greater than about 15% homology to any one of the GPCR peptide ligands disclosed herein and further comprises a characteristic pre-pro motif and/or one or more processing sites, as disclosed herein. For example, but not by way of limitation, the GPCR peptide ligand comprises an amino acid sequence that has greater than about 15% homology to an amino acid sequence comprising any one of SEQ ID NOs: 1-116 or an amino acid sequence of any one of the GPCRs peptide ligands listed in Table 12 and further comprises a characteristic pre-pro motif and/or one or more processing sites. In certain embodiments, the GPCR peptide ligand comprises a nucleotide sequence that has greater than about 15% homology to a nucleotide sequence comprising any one of SEQ ID NOs: 215-230 and further comprises a characteristic pre-pro motif and/or one or more processing sites. In certain embodiments, the GPCR peptide ligand thereof for use in the present disclosure comprises an amino acid sequence that has greater than about 15%, greater than about 20%, greater than about 25%, greater than about 30%, greater than about 35%, greater than about 40%, greater than about 45%, greater than about 50%, greater than about 55%, greater than about 60%, greater than about 65%, greater than about 70%, greater than about 75%, greater than about 80%, greater than about 85%, greater than about 90%, greater than about 91%, greater than about 92%, greater than about 93%, greater than about 94%, greater than about 95%, greater than about 96%, greater than about 97%, greater than about 98% or greater than about 99% homology to any one of the GPCR peptide ligands disclosed herein and further comprises a characteristic pre-pro motif and/or processing sites. For example, but not by way of limitation, the GPCR peptide ligand comprises an amino acid sequence that has greater than about 15% homology, greater than about 20%, greater than about 25%, greater than about 30%, greater than about 35%, greater than about 40%, greater than about 45%, greater than about 50%, greater than about 55%, greater than about 60%, greater than about 65%, greater than about 70%, greater than about 75%, greater than about 80%, greater than about 85%, greater than about 90%, greater than about 91%, greater than about 92%, greater than about 93%, greater than about 94%, greater than about 95%, greater than about 96%, greater than about 97%, greater than about 98% or greater than about 99% homology to an amino acid sequence comprising any one of SEQ ID NOs: 1-116 or an amino acid sequence of any one of the GPCR peptide ligands listed in Table 12 and further comprises a characteristic pre-pro motif and/or one or more processing sites.
Alternaria_brasicicola
Arthrobotrys_oligospora
Ashbya_aceri
Ashbya_gossypii
Aspergillus_clavatus
Aspergillus_flavus
Aspergillus_fumigata
Aspergillus_kawachii
Aspergillus_nidulans
Aspergillus_niger
Aspergillus_oryzae
Aspergillus_ruber
Aspergillus_terreus
Baudoinia_compniacensis
Beauveria_bassiana
Botryosphaeria_parva
Botrytis_ciner_ea
Candida_albicans
Candida_dubliniensis
Candida_glabrata
Candida_guilliermondii
Candida_lusitaniae
Candida_parapsilosis
Candida_tenuis
Candida_tropicalis
Capronia_coronata
Capronia_epimyces
Chaetomium_globosum
Chaetomium_thermophilum
Chryphonectria_parasitica
Claviceps_purpurea
Coccidioides_immitis
Colletotrichum_gloeosporioides
Coniosporium_apollinis
Dactylellina_haptotyla
Debaryomyces_hansenii
Endocarpon_pusillum
Eremothecium_cymbalariae
Fusarium_oxysporum
Fusarium_pseudograminearum
Gaeumannomyces_graminis
Geotrichum_candidum
Gibberella_fujikuroi
Gibberella_moniliformis
Gibberella_zeae
Glarea_lozoyensis
Grosmannia_clavigera
Kazachstania_africana
Kazachstania_naganishii
Kluyveromyces_lactis
Kluyveromyces_marxianus
Kluyveromyces_waltii
Komagataella_pastorts
Kuraishia_capsulata
Lachancea_kluyveri
Lachancea_thermotolerans
Lodderomyces_elongisporus
Magnaporthe_oryzae
Magnaporthe_poae
Marssonina_brunnea
Metarhizium_acridum
Metarhizium_anisopliae
Mycosphaerella_graminicola
Nectria_haematococca
Neosartorya_fischeri
Neurospora_crassa
Neurospora_tetrasperma
Ogataea_parapolymorpha
Ophiostoma_piceae
Paracoccidioides_lutzii
Penicillium_chrysogenum
Penicillium_digitatum
Penicillium_oxalicum
Penicillium_roqueforti
Phaeosphaeria_nodorum
Pichia_sorbitophila
Podospora_anserina
Pseudogymnoascus_destructans
Pyrenophora_teres_f_teres
Pyrenophora_tritici-repentis
Saccharomyces_bayanus
Saccharomyces_castellii
Saccharomyces_cerevisiae
Saccharomyces_dairenensis
Saccharomyces_mikatae
Saccharomyces_paradoxis
Scheffersomyces_stipitis
Schizosaccharomyces_japonicus
Schizosaccharomyces_octosporus
Schizosaccharomyces_pombe
Sclerotinia_borealis
Sclerotinia_sclerotiorum
Sordaria_macrospora
Sporothrix_schenckii
Tetrapisispora_blattae
Tetrapisispora_phaffii
Thielavia_heterothallica
Togninia_minima
Torulaspora_delbrueckii
Trichoderma_atroviridis
Trichoderma_jecorina
Trichoderma_virens
Tuber_melanosporum
Vanderwaltozyma_polyspora_1
Vanderwaltozyma_polyspora_2
Vernetllium_alfalfae
Verticillium_dahliae
Wickerhamomyces_ciferrii
Yarrowia_lipolytica
Zygosaccharomyces_bailii
Zygosaccharomyces_rouxii
In certain embodiments, the secretable GPCR peptide ligand can comprise one or more secretion signal sequences. Non-limiting examples of such secretion signal sequences are provided in Tables 4 and 7. In certain embodiments, the one or more secretion signal sequences are located at the N-terminus of a secretable GPCR peptide ligand. In certain embodiments, a Kex2 processing site and/or a Ste13 processing site or a homolog thereof can be present between the amino acid sequence of the secretion signal sequence and the secretable GPCR peptide ligand.
In certain embodiments, the GPCR ligand, e.g., GPCR peptide ligand, increases the activation of a GPCR disclosed herein from about 1.1 to about 20 fold, e.g., from about 2 to about 20 fold, from about 5 to about 20 fold, from about 10 to about 20 fold, from about 15 to about 20 fold, from about 1.1 to about 15 fold, from about 1.1 to about 10 fold, from about 1.1 to about 5 fold or from about 1.1 to about 2 fold. In certain embodiments, a GPCR ligand, e.g., GPCR peptide ligand, has an EC50 range of, or of about, 1 to 104 nM, e.g., from about 102 nM to about 103 nM, from about 102 nM to about 104 nM or from about 103 nM to about 104 nM for a GPCR disclosed herein.
Identification of GPCRs and Ligands
The present disclosure further provides methods for mining and characterizing GPCRs, e.g., fungal GPCRs, and their genetically encoded peptide ligands, e.g., using genomic data as input.
In certain embodiments, an alpha-factor-like GPCR peptide ligand and its cognate GPCR can be identified in scientific literature and databases identifiable by skilled persons such as NCBI, Genbank, Interpro, PFAM or Uniprot, and/or using a “genome-mining” approach such as described in Examples 1 and 2 of the present disclosure, such as using the method reported by Martin et al.66 and/or Miguel Jimenez, Doctoral Thesis, Columbia University 2016, and subsequently tested for the ability of an identified GPCR peptide ligand to bind to and activate a GPCR described herein.
In certain embodiments, GPCRs can be identified by searching protein and genomic databases for proteins and/or genes with homology (structural or sequence homology) to known GPCRs, e.g., GPCRs disclosed herein. In certain embodiments, the protein and/or genomic database to be searched is selected from the group consisting of NCBI, Genbank, Interpro, PFAM, Uniprot and a combination thereof.
In certain embodiments, GPCRs can be identified by searching protein and genomic databases for proteins and/or genes with homology (structural or sequence homology) to the S. cerevisiae Ste2 receptor and/or Ste3 receptor. In certain embodiments, the genome-mined GPCRs have an amino acid sequence homology of at least about 15%, e.g., from about 17% to about 68% homology, to S. cerevisiae Ste2 or a motif of Ste2.
In certain embodiments, GPCRs can be identified by searching protein and genomic databases for proteins and/or genes that have conserved regions that is at least about 15%, e.g., from about 17% to about 68%, homologous to the core seven transmembrane helix domain of the S. cerevisiae Ste2 receptor, e.g., Y17 to N301 or one or more of its constituent transmembrane helices, or one of its constituent intracellular signaling loops and associated transmembrane helices, e.g., the amino acid residues spanning from the fifth to the sixth transmembrane helix.
In certain embodiments, GPCRs can be identified by searching protein and genomic databases for proteins and/or genes with homology (structural or sequence homology) to a GPCR disclosed herein. For example, but not by way of limitation, GPCRs can be identified by searching protein and genomic databases for proteins and/or genes with homology (structural or sequence homology) to a GPCR comprising an amino acid sequence comprising any one of SEQ ID NOs: 117-161, a GPCR comprising an amino acid sequence provided in Table 11 and/or a GPCR encoded by a nucleotide sequence comprising any one of SEQ ID NOs: 168-211. In certain embodiments, the genome-mined GPCRs have an amino acid sequence homology of at least about 15%, e.g., from about 17% to about 68% homology, to the GPCR comprising an amino acid sequence comprising any one of SEQ ID NOs: 117-161 and/or the GPCR comprising an amino acid sequence provided in Table 11. In certain embodiments, the genome-mined GPCRs show an amino acid sequence homology of at least about 15%, e.g., from about 17% to about 68% homology, to the GPCR encoded by a nucleotide sequence comprising any one of SEQ ID NOs: 168-211.
The present disclosure provides a method for the identification of a G-protein coupled receptor (GPCR) to be expressed in a genetically-engineered cell. For example, but not by way of limitation, the method can include searching a protein and/or genomic database for a protein and/or a gene with homology to S. cerevisiae Ste2 receptor and/or Ste3 receptor. In certain embodiments, the identified GPCR has an amino acid sequence that is at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% homologous to the S. cerevisiae Ste2 receptor and/or Ste3 receptor or a motif thereof. In certain embodiments, the identified GPCR has an amino acid sequence that is at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% homologous to the core seven transmembrane helix domain of the S. cerevisiae Ste2 receptor, e.g., Y17 to N301 or one or more of its constituent transmembrane helices, or one of its constituent intracellular signaling loops and associated transmembrane helices, e.g., the amino acid residues spanning from the fifth to the sixth transmembrane helix.
The present disclosure further provides a method for the identification of a GPCR to be expressed in a genetically-engineered cell. For example, but not by way of limitation, the method can include searching a protein and/or genomic database for a protein and/or a gene with homology to a GPCR disclosed herein. In certain embodiments, the identified GPCR has an amino acid sequence that is at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% homologous to a GPCR comprising an amino acid sequence comprising any one of SEQ ID NOs: 117-161 and/or a GPCR comprising an amino acid sequence provided in Table 11. In certain embodiments, the identified GPCR has a nucleotide sequence that is at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% homologous to a GPCR encoded by a nucleotide sequence comprising any one of SEQ ID NOs: 168-211.
In certain embodiments, the genome-mined GPCRs have an amino acid sequence having greater than about 15% homology, e.g., greater than about 20%, greater than about 25%, greater than about 30%, greater than about 35%, greater than about 40%, greater than about 45%, greater than about 50%, greater than about 55%, greater than about 60%, greater than about 65%, greater than about 70%, greater than about 75%, greater than about 80%, greater than about 85%, greater than about 90%, greater than about 91%, greater than about 92%, greater than about 93%, greater than about 94%, greater than about 95%, greater than about 96%, greater than about 97%, greater than about 98% or greater than about 99% homology, to any one of the GPCRs disclosed herein and further comprise a characteristic seven transmembrane helix domain. For example, but not by way of limitation, a genome-mined GPCR of the present disclosure comprises an amino acid sequence that has greater than about 15% homology to an amino acid sequence comprising any one of SEQ ID NOs: 117-161 and/or a GPCR comprising an amino acid sequence provided in Table 11 and further comprises a characteristic seven transmembrane helix domain. In certain embodiments, a genome-mined GPCR of the present disclosure comprises a nucleotide sequence that has greater than about 15% homology to a nucleotide sequence comprising any one of SEQ ID NOs: 168-211 and further comprises a characteristic seven transmembrane helix domain.
In certain embodiments, GPCR ligands can be identified by searching protein and genomic databases for proteins, peptides and/or genes with homology (structural or sequence homology) to known GPCR ligands, e.g., GPCR ligands disclosed herein or pheromone genes, e.g., of yeast (e.g., S. cerevisiae). For example, but not by way of limitation, the identified GPCR ligand has an amino acid sequence that is at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% homologous to a GPCR ligand that has an amino acid sequence comprising any one of SEQ ID NOs: 1-116, a GPCR ligand that has an amino acid sequence provided a Table 12 or a fungal pheromone. In certain embodiments, the identified GPCR ligand has a nucleotide sequence that is at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% homologous to a nucleotide sequence comprising any one of SEQ ID NOs: 215-230.
Alternatively and/or additionally, GPCR ligands can be identified from genomes of fungal species by identifying genes, proteins and/or peptides that include regions that are homologous to the processing motifs present in the known pheromone genes, as disclosed herein. For example, pheromone genes have a signature architecture that consists of a hydrophobic prepro secretion signal followed by repeats of the putative secreted peptide flanked by proteolitic processing sites, which can be used to identify GPCR ligands that also include such architecture. In particular, the repetitive nature of the pheromone genes enables prediction of active peptides that bind and induce the corresponding GPCR. For example, but not by way of limitation, putative GPCR ligands can be identified by the presence of flanking processing sites such as X-A and X-P dipeptides and/or Kex2-like cleavage sites (KR, QR, NR) that appear between each repeated region (i.e., the repeated region excluding the processing site is the active GPCR ligand). In certain embodiments, identified GPCR ligand genes, protein and/or peptides include flanking processing sites, e.g., often with a single site preceding a short C-terminal peptide that is the active ligand.
In certain embodiments, the genome-mined GPCR ligands have an amino acid sequence that has greater than about 15% homology, e.g., greater than about 20%, greater than about 25%, greater than about 30%, greater than about 35%, greater than about 40%, greater than about 45%, greater than about 50%, greater than about 55%, greater than about 60%, greater than about 65%, greater than about 70%, greater than about 75%, greater than about 80%, greater than about 85%, greater than about 90%, greater than about 91%, greater than about 92%, greater than about 93%, greater than about 94%, greater than about 95%, greater than about 96%, greater than about 97%, greater than about 98% or greater than about 99% homology, to any one of the GPCR peptide ligands disclosed herein and further comprise a characteristic pre-pro motif and/or one or more processing sites. For example, but not by way of limitation, a genome-mined GPCR peptide of the present disclosure comprises an amino acid sequence that has greater than about 15% homology to an amino acid sequence comprising any one of SEQ ID NOs: 1-116 and/or a GPCR peptide ligand comprising an amino acid sequence provided in Table 12, and further comprises a characteristic pre-pro motif and/or one or more processing sites. In certain embodiments, a genome-mined GPCR peptide ligand of the present disclosure comprises a nucleotide sequence that has greater than about 15% homology to a nucleotide sequence comprising any one of SEQ ID NOs: 215-230, and further comprises a characteristic pre-pro motif and/or one or more processing sites.
In certain embodiments, GPCR ligands can be identified by searching for proteins and/or peptides (or genes that encode such proteins and/or peptides) that have certain conserved features such as, but not limited to, aromatic amino acids at the termini, e.g., tryptophan at the N-terminus, and/or paired cysteines near the termini.
In certain embodiments, a variant GPCR or a variant GPCR ligand can be obtained using a method of directed evolution. The term “directed evolution” means a process wherein random mutagenesis is applied to a protein (e.g., a GPCR or a GPCR peptide ligand), and a selection regime is used to pick out variants that have the desired qualities, such as selecting for an altered binding and/or activation. Accordingly, polynucleotides encoding a GPCR or a GPCR ligand as described herein (e.g., in the Examples) can be genetically mutated using recombinant techniques known to those of ordinary skill in the art, including by site-directed mutagenesis, or by random mutagenesis such as by exposure to chemical mutagens or to radiation, as known in the art. An advantage of directed evolution is that it requires no prior structural knowledge of a protein, nor is it necessary to be able to predict what effect a given mutation will have. In general, in the intercellular signaling system of the present disclosure that includes at least two cells, a first cell is adapted to secrete a peptide configured to activate a GPCR of a second cell as described herein. Because GPCRs couple well to the conserved yeast MAP-kinase signaling cascade36, the fungal mating peptide/GPCR-based intercellular signaling system described herein overcomes limitations of previous intercellular signaling systems and can be harnessed as a source of modular parts for engineering a scalable intercellular signaling system. For example, but not by way of limitation, the GPCRs, disclosed herein, can undergo directed evolution to alter it specificity to a certain ligand, e.g., to increase its binding to a ligand and/or decrease its binding to a ligand.
In certain embodiments, a variant GPCR or a variant GPCR ligand can be obtained using family shuffling to generate new GPCRs that have altered ligand-binding properties. The term “family shuffling” means a process where DNA fragments of a family of related GPCRs are randomly recombined to generate variant GPCRs that are selected for the desired qualities, such as selecting for an altered binding and/or activation. See, e.g., Kikuchi and Harayama (2002) DNA Shuffling and Family Shuffling for In Vitro Gene Evolution. In: Braman J. (eds) In Vitro Mutagenesis Protocols. Methods in Molecular Biology, Vol. 182; and Meyer et al., Library Generation by Gene Shuffling, Curr. Protoc. Mol. Biol. (2014) 105:15.12.1-15.12.7, which are incorporated by reference herein in their entireties.
Cells for use in the intercellular signaling systems of the present disclosure can be cells, e.g., genetically-engineered cells, that express a heterologous GPCR and/or secrete a GPCR ligand. For example, but not by way of limitation, a cell for use in the present disclosure can express one or more GPCR ligands, disclosed herein. In certain embodiments, a cell for use in the present disclosure can express one or more heterologous GPCRs, disclosed herein.
In certain embodiments, the cell for use in the intercellular signaling systems of the present disclosure can be a mammalian cell, a plant cell or a fungal cell. For example, but not by way of limitation, the cell can be a mammalian cell, e.g., a genetically-engineered mammalian cell. In certain embodiments, the cell can be a plant cell, e.g., a genetically-engineered plant cell.
In certain embodiments, the cell can be a fungal cell, e.g., a genetically-engineered fungal cell. For example, but not by way of limitation, the cell can be a cell of the phylum Ascomycota. In certain embodiments, the cells, e.g., two or more cells, of intercellular signaling systems of the present disclosure are cells independently selected from any species of the phylum Ascomycota. In certain embodiments, the cells can be species independently selected from Saccharomyces cerevisiae, Saccharomyces castellii, Vanderwaltozyma polyspora, Torulaspora delbrueckii, Saccharomyces kluyveri, Kluyveromyces lactis, Zygosaccharomyces rouxii, Zygosaccharomyces bailii, Candida glabrata, Ashbya gossypii, Scheffersomyces stipites, Komagataella (Pichia) pastoris, Candida (Pichia) guilliermondii, Candida parapsilosis, Candida auris, Yarrowia lipolytica, Candida (Clavispora) lusitaniae, Candida albicans, Candida tropicalis, Candida tenuis, Lodderomyces elongisporous, Geotrichum candidum, Baudoinia compniacensis, Schizosaccharomyces octosporus, Tuber melanosporum, Aspergillus oryzae, Schizosaccharomyces pombe, Aspergillus (Neosartorya) fischeri, Pseudogymnoascus destructans, Schizosaccharomyces japonicus, Paracoccidioides brasiliensis, Mycosphaerella graminicola, Penicillium chrysogenum, Aspergillus nidulans, Phaeosphaeria nodorum, Hypocrea jecorina, Botrytis cinereal, Beauvaria bassiana, Neurospora crassa, Sporothrix scheckii, Magnaporthe oryzea, Dactylellina haptotyla, Fusarium graminearum, and Capronia coronata.
In certain embodiments, two or more cells of an intercellular signaling system (e.g., all the cells of an intercellular signaling system) can be of the same species of the phylum Ascomycota or cell type. For example, but not by way of limitation, two or more cells (or all the cells) can be Saccharomyces cerevisiae. Alternatively, at least one of the cells within an intercellular signaling system is of a different species of the phylum Ascomycota or cell type.
In certain embodiments, one or more endogenous GPCR genes of the cells and/or one or more endogenous GPCR peptide ligand genes of the cells are knocked out.
For example, but not by way of limitation, the one or more knocked out endogenous GPCR genes can comprise an STE2 gene and/or an STE3 gene. In certain embodiments, one or more of the knocked out endogenous GPCR peptide ligand genes can comprise an MFA1/2 gene, an MFALPHA1/MFALPHA2 gene, a BAR1 gene and/or an SST2 gene. In certain embodiments, the FAR1 gene can be knocked out. In certain embodiments, a cell for use in the present disclosure has one or more, two or more, three or more, four or more, five or more, six or more or all seven of following genes knocked out: STE2, STE3, MFA1/2, MFALPHA1/MFALPHA2, BAR1, SST2 and FAR1.
In certain embodiments, a genetic engineering system is employed to knock out the genes disclosed herein, e.g., one or more endogenous GPCR genes and/or one or more endogenous GPCR peptide ligand genes, in a cell. Various genetic engineering systems known in the art can be used for the methods disclosed herein. Non-limiting examples of such systems include the Clustered regularly-interspaced short palindromic repeats (CRISPR)/Cas system, the zinc-finger nuclease (ZFN) system, the transcription activator-like effector nuclease (TALEN) system, use of yeast endogenous homologous recombination and the use of interfering RNAs.
In certain non-limiting embodiments, a CRISPR/Cas9 system is employed to knock out the one or more endogenous GPCR genes and/or one or more endogenous GPCR peptide ligand genes in a cell. When utilized for genome editing, the system includes Cas9 (a protein able to modify DNA utilizing crRNA as its guide), CRISPR RNA (crRNA, contains the RNA used by Cas9 to guide it to the correct section of host DNA along with a region that binds to tracrRNA (generally in a hairpin loop form) forming an active complex with Cas9) and trans-activating crRNA (tracrRNA, binds to crRNA and forms an active complex with Cas9). The terms “guide RNA” and “gRNA” refer to any nucleic acid that promotes the specific association (or “targeting”) of an RNA-guided nuclease such as a Cas9 to a target sequence such as a genomic or episomal sequence in a cell. gRNAs can be unimolecular (comprising a single RNA molecule, and referred to alternatively as chimeric) or modular (comprising more than one, and typically two, separate RNA molecules, such as a crRNA and a tracrRNA, which are usually associated with one another, for instance by duplexing).
In certain embodiments, the CRISPR/Cas9 system comprises a Cas9 molecule and one or more gRNAs, e.g., 2 gRNAs, comprising a targeting domain that is complementary to a target sequence of one or more endogenous GPCR genes and/or one or more endogenous GPCR peptide ligand genes. For example, but not by way of limitation, the target sequence can be a sequence within a GPCR peptide ligand gene, e.g., a MFA1/2 gene, a MFALPHA1/MFALPHA2 gene, a BAR1 gene and/or an SST2 gene. In certain embodiments, the target sequence is a sequence within a GPCR peptide ligand gene, e.g., an STE2 gene and/or an STE3 gene. In certain embodiments, the target sequence can be a 5′ region flanking the open reading frame of the gene to be knocked out and/or a 3′ region flanking the open reading frame of the gene to be knocked out. For example, but not by way of limitation, a CRISPR/Cas9 system for use in the present disclosure comprises a Cas9 molecule and two gRNAs, where one gRNA targets a 5′ region flanking the open reading frame of the gene to be knocked out and the second gRNA targets a 3′ intron region flanking the open reading frame of the gene to be knocked out. Non-limiting examples of gRNAs are disclosed in Table 8. For example, but not by way of limitation, a gRNA for use in knocking out one or more endogenous GPCR genes and/or one or more endogenous GPCR peptide ligand genes comprises a nucleotide sequence set forth in any one of SEQ ID NOs: 231-253.
In certain embodiments, the gRNAs are administered to the cell in a single vector and the Cas9 molecule is administered to the cell in a second vector. In certain embodiments, the gRNAs and the Cas9 molecule are administered to the cell in a single vector. Alternatively, each of the gRNAs and Cas9 molecule can be administered by separate vectors. In certain embodiments, the CRISPR/Cas9 system can be delivered to the cell as a ribonucleoprotein complex (RNP) that comprises a Cas9 protein complexed with one or more gRNAs, e.g., delivered by electroporation (see, e.g., DeWitt et al., Methods 121-122:9-15 (2017) for additional methods of delivering RNPs to a cell).
In certain embodiments, the two or more cells of the intercellular communication system has a mating type selected from a MA Ta-type and a MA Ta-type.
The cells to be used in the present disclosure can be genetically-engineered using recombinant techniques known to those of ordinary skill in the art. Production and manipulation of the polynucleotides described herein are within the skill in the art and can be carried out according to recombinant techniques described, for example, in Sambrook et al. 1989. Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. and Innis et al. (eds). 1995. PCR Strategies, Academic Press, Inc., San Diego.
The present disclosure provides intercellular signaling systems that comprise at least two cells that can communicate with one another and methods of promoting intercellular signaling between at least two cells. For example, but not by way of limitation, an intercellular signaling system of the present disclosure includes at least two or more, at least three or more, at least four or more, at least five or more, at least six or more, at least seven or more, at least eight or more, at least nine or more, at least ten or more, at least fifteen or more, at least twenty or more, at least thirty or more, at least forty or more or at least fifty or more cells that can communicate with one another.
In certain embodiments, at least one of the cells (e.g., each of the cells) of the intercellular signaling system expresses a heterologous GPCR. In certain embodiments, at least one of the cells of the intercellular signaling system express more than one heterologous GPCR. For example, but not by way of limitation, one or more cells of the intercellular signaling system can express one, two, three, four, five or more heterologous GPCRs, e.g., where each GPCR binds to and are activated by different ligands. In certain embodiments, the heterologous GPCRs are encoded by a nucleic acid that is present within the cell, e.g., the cells comprise a nucleic acid that encodes at least one heterologous GPCR. The GPCR can be heterologous by virtue of having its origin in another type of organism, e.g., a different species of fungus, and/or being a variant and/or derivative of a native GPCR in the same or different type of organism, e.g., a product of directed evolution. Non-limiting examples of GPCRs that can be encoded by the nucleic acid are disclosed herein.
In certain embodiments, at least one of the cells (e.g., each of the cells) of the intercellular signaling system expresses a ligand, e.g., a GPCR ligand. In certain embodiments, at least one of the cells of the intercellular signaling system express more than one ligand. For example, but not by way of limitation, one or more cells of the intercellular signaling system can express one, two, three, four, five or more ligands, e.g., where each ligand binds to and activate different GPCRs. In certain embodiments, the ligand, e.g., a protein or peptide ligand, is encoded by a nucleic acid that is present within the cell, e.g., the cells comprise a nucleic acid that encodes at least one ligand. In certain embodiments, each cell of the intercellular signaling system includes a nucleic acid that encodes a secretable ligand, e.g., a secretable protein or a secretable peptide. In certain embodiments, the nucleic acid encodes a peptide, e.g., a secretable GPCR peptide ligand. For example, but not by way of limitation, activation of a GPCR expressed by a cell results in the expression and secretion of the secretable GPCR peptide ligand from the cell, e.g., by signaling through a G-protein signaling pathway. The secretable GPCR peptide ligand can, in turn, bind to and activate a second GPCR on a separate cell within the intercellular signaling system. Non-limiting examples of secretable GPCR peptide ligands that can be encoded by the nucleic acid are disclosed herein.
In certain embodiments, one or more cells of the intercellular signaling pathway can include a nucleic acid encoding an essential gene. An “essential gene,” as used herein, refers to a gene that when expressed in a cell is required for the growth and/or survival of the cell, e.g., under any growth condition. Non-limiting examples of essential genes include PKC1, RPB11 and SEC4. Additional non-limiting examples of essential genes in yeast are disclosed in Kofed et al., G3 (Bethesda) 5(9):1879-1887 (2015). For example, but not by way of limitation, the essential gene can be SEC4.
In certain embodiments, one or more cells of the intercellular signaling pathway can include a nucleic acid encoding a conditionally essential gene. A “conditionally essential gene,” as used herein, refers to a gene that is essential for growth and/or survival under certain conditions but not others, e.g., in the absence of an essential media component. In certain embodiments, a conditionally essential gene can be a gene that is required to generate an essential amino acid. Non-limiting examples of conditionally essential genes include HIS3 and TRP1.
In certain embodiments, one or more cells of the intercellular signaling pathway can include a nucleic acid encoding a toxic gene. A “toxic gene,” as used herein, refers to a gene that results in the death of a cell under certain conditions, e.g., where the gene encodes a protein that coverts a compound present in the media into a toxic compound. A non-limiting example of a toxic gene include URA3. For example, but not by way of limitation, URA3 encodes a protein that converts 5-fluoroorotic acid (5-FOA) present in the media to 5-fluorouracil, which is toxic.
In certain embodiments, such essential genes, conditionally essential genes and toxic genes can be used to engineer mutually-dependent communities, where one or more cells within a community rely on or are suppressed by the expression and secretion of a GPCR peptide ligand from other distinct cells within the same community.
In certain embodiments, one or more cells of the intercellular signaling pathway can include a nucleic acid encoding a product of interest. Non-limiting examples of such products of interest include hormones, toxins, receptors, fusion proteins, regulatory factors, growth factors, complement system factors, clotting factors, anti-clotting factors, kinases, cytokines, CD proteins, interleukins, therapeutic proteins, diagnostic proteins, enzymes, biosynthetic pathways, antibiotics and antibodies.
In certain embodiments, one or more cells of the intercellular signaling system can include a nucleic acid that encodes a detectable reporter. For example, but not by way of limitation, a detectable reporter includes a label, e.g., a compound capable of emitting a detectable signal, including but not limited to radioactive isotopes, fluorophores, chemiluminescent dyes, chromophores, enzymes, enzymes substrates, enzyme cofactors, enzyme inhibitors, dyes, metal ions, nanoparticles, metal sols, ligands (such as biotin, avidin, streptavidin or haptens) and the like. The term “fluorophore” refers to a substance or a portion thereof which is capable of exhibiting fluorescence in a detectable image (e.g., as seen for fluorescent reporters in the Examples). In certain embodiments, the term “labeling signal” as used herein indicates the signal emitted from the label that allows detection of the label, including but not limited to radioactivity, fluorescence, chemiluminescence, production of a compound in outcome of an enzymatic reaction (e.g., production of colored compounds) and the like.
The detection of the reporter can be performed by various methods identifiable by those skilled in the art, such as in vitro methods: fluorescence, absorbance, mass spectrometry, flow cytometry colorimetric, visual, UV, gas chromatography, liquid chromatography, an electronic output, activation of ion channels, protein gels, Western blot, thin layer chromatography and radioactivity. In particular a labeling signal can be quantitative or qualitatively detected with these techniques as will be understood by a skilled person. For example, but not by way of limitation, a fluorescent protein such as GFP can be detected with an excitation range of 485 and an emission range of 515, and mRFP can be detected with an excitation range of 580 and an emission range of 610. Other fluorescent proteins include without limitation sfGFP, deGFP, eGFP, Venus, YFP, Cerulean, Citrine, CFP, eYFP, eCFP, mRFP, mCherry, mmCherry. Other reportable molecular components do not require excitation to be detected; for example, colorimetric reportable molecular components can have a detectable color without fluorescent excitation. Other detectable signals include dyes that can be bound to genetic molecular components and then released upon an activity (e.g., sequestration, FRET, digestion).
In certain embodiments, one or more cells of the intercellular signaling system can include a nucleic acid that encodes a sensor, e.g., a protein (e.g., a receptor such as a GPCR), that detects one or more analytes or agents of interest that differ from the ligands that interact with the heterologous GPCR expressed by the cell. Non-limiting examples of such analytes or agents of interest include heavy metals, metabolites, small molecules and light. Additional non-limiting examples of such analytes or agents of interest include human disease agents (human pathogenic agents), agricultural agents, industrial/model organism agents and bioterrorism agents. See U.S. Publication No. 2017/0336407, the contents of which are disclosed by reference herein in its entirety.
In certain embodiments, an intercellular signaling system of the present disclosure includes a cell, e.g., a genetically-engineered cell, that expresses at least one heterologous GPCR. In certain embodiments, the heterologous GPCR is encoded by a nucleic acid that is present within the cell. For example, but not by way of limitation, an intercellular signaling system of the present disclosure includes a cell that comprises at least one nucleic acid encoding a heterologous GPCR present within the cell. In certain embodiments, the GPCR is activated by an exogenously supplied ligand. Non-limiting examples of ligands, e.g., a synthetic ligand, that can activate a GPCR are described herein.
In certain embodiments, an intercellular signaling system of the present disclosure includes a cell, e.g., a genetically-engineered cell, that expresses at least one secretable GPCR ligand, e.g., a GPCR peptide ligand. In certain embodiments, the secretable GPCR ligand is encoded by nucleic acid that are present within the cell. For example, but not by way of limitation, an intercellular signaling system of the present disclosure includes a cell that comprises at least one nucleic acid that encodes a secretable GPCR ligand, e.g., a GPCR peptide ligand. In certain embodiments, the expression of the secretable GPCR ligand can be activated by a ligand-inducible promoter. In certain embodiments, the expression of the secretable GPCR ligand can be induced by the activation of an endogenous GPCR or a heterologous GPCR that results in the expression of the secretable GPCR ligand.
In certain embodiments, an intercellular signaling system of the present disclosure includes a cell, e.g., a genetically-engineered cell, that expresses at least one heterologous GPCR and at least one secretable GPCR ligand, e.g., a GPCR peptide ligand. In certain embodiments, the secretable GPCR ligand expressed by the genetically-engineered cell does not activate the heterologous GPCR of the same cell. In certain embodiments, the secretable GPCR ligand expressed by the genetically-engineered cell selectively interacts with and activates the heterologous GPCR of the same cell. In certain embodiments, the heterologous GPCRs and secretable GPCR ligand are encoded by nucleic acids that are present within the cells. For example, but not by way of limitation, an intercellular signaling system of the present disclosure includes at least one cell, where the cell includes at least one nucleic acid encoding a first GPCR and at least one nucleic acid that encodes a first secretable GPCR ligand, e.g., a GPCR peptide ligand. In certain embodiments, the secretable GPCR peptide ligand that is secreted from the cell selectively interacts with and activates the heterologous GPCR expressed by the cell. Alternatively, the secretable GPCR peptide ligand that is secreted from the cell does not activate the heterologous GPCR expressed by the cell.
In certain embodiments, an intercellular signaling system of the present disclosure includes two or more cells, where the first cell expresses at least one secretable GPCR ligand, e.g., a GPCR peptide ligand, and the second cell expresses at least one heterologous GPCR. In certain embodiments, the GPCR ligand secreted by the first cell selectively interacts with and activates the heterologous GPCR expressed by the second cell. In certain embodiments, the heterologous GPCRs and secretable GPCR ligand are encoded by nucleic acids that are present within the cells. For example, but not by way of limitation, an intercellular signaling system of the present disclosure includes two or more cells, where one cell includes at least one nucleic acid that encodes a first secretable GPCR ligand, e.g., a GPCR peptide ligand, and the second cell includes at least one nucleic acid encoding a second GPCR. In certain embodiments, the first secretable GPCR peptide ligand that is secreted from the first cell selectively interacts with and activates the second GPCR expressed by the second cell. In certain embodiments, the first cell can further express a heterologous GPCR (e.g., different from the heterologous GPCR expressed by the second cell and/or which is not activated by the secretable GPCR ligand expressed by the first cell) and the second cell can further express a secretable GPCR ligand (e.g., that is different from the secretable GPCR ligand expressed by the first cell and/or does not activate the heterologous GPCR expressed by the second cell).
In certain embodiments, an intercellular signaling system of the present disclosure includes two or more cells, where the first cell expresses at least one heterologous GPCR and at least one secretable GPCR ligand, e.g., a GPCR peptide ligand, and the second cell expresses at least one heterologous GPCR. In certain embodiments, the heterologous GPCR expressed by the second cell is different from the heterologous GPCR expressed by the first cell, e.g., are selectively activated by different ligands. In certain embodiments, the GPCR ligand secreted by the first cell selectively interacts with and activates the heterologous GPCR expressed by the second cell. In certain embodiments, the heterologous GPCRs and secretable GPCR ligand are encoded by nucleic acids that are present within the cells. For example, but not by way of limitation, an intercellular signaling system of the present disclosure includes two or more cells, where one cell includes at least one nucleic acid encoding a first GPCR and at least one nucleic acid that encodes a first secretable GPCR ligand, e.g., a GPCR peptide ligand, and the second cell includes at least one nucleic acid encoding a second GPCR. In certain embodiments, the first secretable GPCR peptide ligand that is secreted from the first cell selectively interacts with and activates the second GPCR expressed by the second cell. In certain embodiments, the first cell is the same cell as the second cell.
In certain embodiments, an intercellular signaling system of the present disclosure includes two or more cells, where a first cell expresses a first heterologous GPCR and a first secretable GPCR ligand, e.g., a first GPCR peptide ligand, and a second cell expresses a second heterologous GPCR and a second secretable GPCR ligand, e.g., a second GPCR peptide ligand. In certain embodiments, the heterologous GPCRs and secretable GPCR ligands are encoded by nucleic acids that are present within the cells. For example, but not by way of limitation, an intercellular signaling system of the present disclosure includes two or more cells, where one cell includes at least one nucleic acid encoding a first GPCR and at least one nucleic acid that encodes a first secretable GPCR ligand, e.g., a GPCR peptide ligand, and the second cell includes at least one nucleic acid encoding a second GPCR and at least one nucleic acid that encodes a second secretable GPCR ligand, e.g., a GPCR peptide ligand.
In certain embodiments, the first heterologous GPCR and the second heterologous GPCR have sequence homologies of less than about 30% and/or the first secretable GPCR ligand and the second secretable GPCR ligand have sequence homologies of less than about 40%, e.g., to generate an orthogonal intercellular signaling system. For example, but not by way of limitation, an intercellular signaling system of the present disclosure can include (i) a first genetically-engineered cell that expresses a first heterologous GPCR and/or a first secretable GPCR peptide ligand and (ii) a second cell expresses a second heterologous GPCR and/or a second secretable GPCR peptide ligand, wherein the first heterologous GPCR and the second heterologous GPCR have sequence homologies of less than about 30%, e.g., from about 1% to about 29% or from about 0% to about 29%, and/or the first secretable GPCR peptide ligand and the second secretable GPCR peptide ligand have sequence homologies of less than about 40%, e.g., from about 1% to about 39% or from about 0% to about 39%.
In certain embodiments, the first secretable GPCR peptide ligand that is secreted from the first cell selectively interacts with and activates the second GPCR expressed by the second cell. In certain embodiments, the second secretable GPCR peptide ligand that is secreted from the second cell selectively interacts with and activates the first GPCR expressed by the second cell. Alternatively, the second secretable GPCR peptide ligand that is secreted from the second cell does not interact with and activate the first GPCR expressed by the second cell.
In certain embodiments, an intercellular signaling system of the present disclosure can include a third cell, where the third cell expresses a third heterologous GPCR and/or a third GPCR ligand. For example, but not by way of limitation, the third cell can include at least one nucleic acid encoding a third GPCR and/or at least one nucleic acid that encodes a third secretable GPCR ligand, e.g., a GPCR peptide ligand. For example, but not by way of limitation, the second secretable GPCR peptide ligand that is secreted from the second cell selectively interacts with and activates the third GPCR expressed by the third cell. For example, but not by way of limitation, an intercellular signaling system of the present disclosure can include a third cell, where the third cell includes at least one nucleic acid encoding a third GPCR and at least one nucleic acid that encodes a third secretable GPCR ligand, e.g., a GPCR peptide ligand. For example, but not by way of limitation, the second secretable GPCR peptide ligand that is secreted from the second cell selectively interacts with and activates the third GPCR expressed by the third cell. Alternatively and/or additionally, the first secretable GPCR peptide ligand that is secreted from the first cell selectively interacts with and activates the third GPCR expressed by the third cell.
In certain embodiments, an intercellular signaling system of the present disclosure can include a fourth cell (or fifth, sixth or seventh, etc. cell) where the fourth cell (or fifth, sixth or seventh, etc. cell) includes a nucleic acid encoding a fourth (or fifth, sixth or seventh, etc.) GPCR and/or a nucleic acid that encodes a fourth (or fifth, sixth or seventh, etc.) secretable GPCR ligand, e.g., GPCR peptide ligand. For example, but not by way of limitation, the third secretable GPCR peptide ligand that is secreted from the third cell selectively interacts with and activates the fourth GPCR expressed by the fourth cell. In certain embodiments, two or more cells of an intercellular signaling system disclosed herein can express the same secretable GPCR ligand that selectively interacts with and activates a GPCR expressed by one or more cells within the system. Alternatively and/or additionally, one or more cells of an intercellular signaling system disclosed herein can express a secretable GPCR ligand that selectively interacts with and activates a GPCR that is expressed by two or more cells within the system.
In certain embodiments, the intercellular signaling system networks described herein can have a daisy chain network topology. For example, but not by way of limitation, in each intermediate cell of the network, the GPCR peptide ligand secreted from a cell that immediately precedes the intermediate cell in the topology of the intercellular signaling system network is different from the secretable GPCR peptide ligand secreted from the intermediate cell. In addition, the GPCR expressed by the intermediate cell is different from the GPCR expressed by a cell that immediately precedes the intermediate cell and expressed by a cell that immediately follows the intermediate cell. The terms “precedes” and “follows” refer to the cell-to-cell flow of an intercellular signal through the network topology. In certain embodiments, a daisy chain network topology can be a daisy chain linear network topology or a daisy chain ring network topology. In certain embodiments, a daisy chain linear network topology or a daisy chain ring network topology can further comprise one or more branches that extend from one or more intermediary cells in the network topology.
In certain embodiments, the intercellular signaling system networks described herein can have a star network topology. For example, but not by way of limitation, a “star” type of network comprises branches, e.g., a cell or cells, that can be connected to each other through a singular common link, e.g., cell.
In certain embodiments, the intercellular signaling system networks described herein can have a bus topology. For example, but not by way of limitation, a “bus” type of network comprises cells that can be connected to each other through a singular common link, e.g., cell.
In certain embodiments, the intercellular signaling system networks described herein can have a branched topology. For example, but not by way of limitation, a “branched” type of network comprises one or more branches, e.g., a cell or cells, that extend from one or more intermediary cells.
In certain embodiments, the intercellular signaling system networks described herein can have a ring topology. For example, but not by way of limitation, a “ring” type of network comprises cells that are connected in a manner where the last cell in the chain is connected back to the first cell in the chain.
In certain embodiments, the intercellular signaling system networks described herein can have mesh topology. For example, but not by way of limitation, a “mesh” type of network is a network where all the cells with the network are connected to as many other cells as possible.
In certain embodiments, the intercellular signaling system networks described herein can have a hybrid topology. For example, but not by way of limitation, a “hybrid” type of network is a network that includes a combination of two or more topologies.
In certain embodiments, a network of can include one or more of these network subtypes, e.g., a branched type network, a bus type network, a ring network, a mesh network, a hybrid network, a star type network and/or a daisy chain network, joined by one or more nodes, e.g., cells. See, for example,
In certain embodiments, a cell can include one or more nucleic acids encoding one or more heterologous GPCRs, e.g., two or more, three or more or four or more nucleic acids to encode two or more, three or more or four or more heterologous GPCRs. Alternatively or additionally, a single nucleic acid can encode more than one heterologous GPCR, e.g., two or more, three or more or four or more heterologous GPCRs. In certain embodiments, a cell can include one or more nucleic acids encoding one or more secretable GPCR ligands, e.g., two or more, three or more or four or more nucleic acids to encode two or more, three or more or four or more secretable GPCR ligands. Alternatively and/or additionally, a single nucleic acid can encode more than one secretable GPCR ligand, e.g., two or more, three or more or four or more secretable GPCR ligands.
In certain embodiments, nucleic acids of the present disclosure can be introduced into the cells of the intercellular communication system using vectors, such as plasmid vectors, and cell transformation techniques such as electroporation, heat shock and others known to those skilled in the art and described herein. In certain embodiments, the genetic molecular components are introduced into the cell to persist as a plasmid or integrate into the genome. In certain embodiments, the cells can be engineered to chromosomally integrate a polynucleotide of one or more genetic molecular components described herein, using methods identifiable to skilled persons upon reading the present disclosure.
In certain embodiments, a nucleic acid encoding a GPCR or a secretable GPCR ligand is introduced into the yeast cell either as a construct or a plasmid. In certain embodiments, a nucleic acid encoding a GPCR or a secretable GPCR peptide ligand can comprise one or more regulatory regions such as promoters, transcription factor binding sites, operators, activator binding sites, repressor binding sites, enhancers, protein-protein binding domains, RNA binding domains, DNA binding domains, and other control elements known to a person skilled in the art. For example, but not by way of limitation, a nucleic acid encoding a GPCR or a secretable GPCR peptide ligand is introduced into the yeast cell either as a construct or a plasmid in which it is operably linked to a promoter active in the yeast cell or such that it is inserted into the yeast cell genome at a location where it is operably linked to a suitable promoter.
Non-limiting examples of suitable yeast promoters include, but are not limited to, constitutive promoters pTef1, pPgk1, pCyc1, pAdh1, pKex1, pTdh3, pTpi1, pPyk1 and pHxt7 and inducible promoters pGal1, pCup1, pMet15, pFig1 and pFus1. For example, but not by way of limitation, a nucleic acid encoding the GPCR can include a constitutively active promoter, e.g., pTdh3. In certain embodiments, a nucleic acid encoding the secretable GPCR peptide ligand can include an inducible promoter, e.g., pFus1 or pFig1. In certain embodiments, a nucleic acid encoding the secretable GPCR peptide ligand can include a constitutively active promoter, e.g., pAdh1.
In certain embodiments, a nucleic acid encoding a GPCR or a secretable GPCR ligand can be inserted into the genome of the cell, e.g., yeast cell. For example, but not by way of limitation, one or more nucleic acids encoding a GPCR or a secretable GPCR ligand can be inserted into the Ste2, Ste3 and/or HO locus of the cell. In certain embodiments, the one or more nucleic acids can be inserted into one or more loci that minimally affects the cell, e.g., in an intergenic locus or a gene that is not essential and/or does not affect growth, proliferation and cell signaling.
The present disclosure further provides methods for using the intercellular signaling systems described herein.
In certain embodiments, the intercellular signaling systems described herein are useful for applications such as synthetic biology, computing, biomanufacturing of biofuels, pharmaceuticals or food additives using yeast, biological sensors, biomaterials, logic gates, switches, screening platform for drug development and toxicology, precision diagnostics tools, model systems to study cell signaling and for artificial plant, animal and human tissues, secretion of peptide and/or protein therapeutics, secretion of small molecule therapeutics, among others.
In certain embodiments, the intercellular signaling systems of the present disclosure can be used for the generation of pharmaceuticals and/or therapeutics. For example, but not by way of limitation, the intercellular signaling systems of the present disclosure can be used for the generation of pharmaceuticals and/or therapeutics that require the assembly of multiple components in a coordinated manner, where each cell of the intercellular signaling system is configured to produce a component of the pharmaceutical. For example, but not by way of limitation, such methods can include the use of a intercellular signaling system that includes a first cell (or a first group of cells), e.g., a yeast cell, that senses a target of interest and communicates with a second cell (or a second group of cells), e.g., a yeast cell, (e.g., by secretion of a ligand that binds to a GPCR expressed by the second cell) where the second cell (or second group of cells) secretes a therapeutic of interest or an intermediate of the therapeutic of interest, e.g., an antibiotic or an intermediate of the antibiotic. Alternatively and/or additionally, such methods can include a intercellular signaling system that includes a network in which a first cell (or a first group of cells), e.g., a yeast cell, senses a target of interest and communicates with second cell (or a second group of cells), e.g., a yeast cell, to analyze the sensed data and in which a third cell (or a third group of cells) cell, e.g., a yeast cell, secretes a therapeutic of interest (or an intermediate of the therapeutic of interest) in response to the sensed target of interest. In certain embodiments, the target of interest can include a marker, indicator and/or biomarker of a disorder and/or disease.
In certain embodiments, a method for the production of a pharmaceutical and/or therapeutic includes providing an intercellular signaling system disclosed herein. For example, but not by way of limitation, an intercellularly signaling system for use in methods for the production of a pharmaceutical and/or therapeutic can include two cells, e.g., two genetically-engineered cells, e.g., two genetically-engineered yeast strains. In certain embodiments, the first cell, e.g., the first genetically modified cell, of the intercellular signaling system, expresses a GPCR, e.g., a heterologous GPCR, that can be activated by a target of interest, e.g., an indicator, biomarker and/or marker of a particular disease or disorder. Upon detection of the target of interest, the first genetically modified cell expresses a secretable GPCR ligand that can selectively activate a heterologous GPCR expressed by the second cell, e.g., second genetically modified cell. Upon activation of the heterologous GPCR expressed by the second cell, the second cell produces a product of interest, e.g., a pharmaceutical and/or a therapeutic. For example, but not by way of limitation, the first genetically modified cell expresses a GPCR, e.g., a heterologous GPCR, that can be activated by different levels of glucose. Upon detection of certain levels of glucose, the first genetically modified cell expresses a secretable GPCR ligand (e.g., the amount of GPCR ligand produced can depend on the level of glucose detected) that can selectively activate the heterologous GPCR expressed by the second cell, e.g., second genetically modified cell. Upon activation of the heterologous GPCR expressed by the second cell, the second cell produces and secretes different insulin levels depending on the level of glucose detected.
In certain embodiments, the intercellular signaling systems of the present disclosure can be used for spatial control of gene expression and/or temporal control of gene expression.
In certain embodiments, the intercellular signaling systems of the present disclosure can be used for generating biomaterials.
In certain embodiments, the intercellular signaling systems of the present disclosure can be used for biosensing. For example, but not by way of limitation, one or more cells of an intercellular signaling system herein can express a receptor (e.g., a GPCR) or other sensing/responsive module (e.g., by introducing a nucleic acid encoding the receptor or sensing/responsive module) that is responsive, e.g., can bind to, one or more agents (molecules) of interest. Non-limiting examples of agents of interest include human disease agents (human pathogenic agents), agricultural agents, industrial and model organism agents, bioterrorism agents and heavy metal contaminants. Human disease agents include, but are not limited to, infectious disease agents, oncological disease agents, neurodegenerative disease agents, kidney disease agents, cardiovascular disease agents, clinical chemistry assay agents, and allergen and toxin agents. Additional non-limiting examples of such agents of interest include hormones, sugars, peptides, metals, metalloids, lipids, biomarkers and combinations thereof. Further non-limiting examples of agents of interests and GPCRs for use in detecting such agents of interest, are disclosed in U.S. Publication No. 2017/0336407, the contents of which are disclosed by reference herein in its entirety.
In certain embodiments, the sensing of an agent of interest by one or more cells of an intercellular signaling system can result in the production and/or secretion of a product of interest by other cells within the intercellular signaling system. For example, but not by way of limitation, the product of interest can be a hormone, toxin, receptor, fusion protein, regulatory factor, growth factor, complement system factor, enzyme, clotting factor, anti-clotting factor, kinase, cytokine, CD protein, interleukins, therapeutic protein, diagnostic protein, biosynthetic pathway and antibody. Such intercellular signaling systems can produce a product of interest in response to an agent of interest. This sense-and-respond behavior can be modulated by building any type of network topology referenced herein (e.g., bus, daisy chain, etc.). In certain embodiments, the sense-and-respond behavior can be tuned such that specific input concentrations lead to desired output concentrations. In certain embodiments, a first cell (or first group of cells) of an intercellular signaling pathway can include a nucleic acid that encodes a receptor or other sensing/responsive module responsive to an agent of interest and include a second cell (or second group of cells) within the same intercellular signaling pathway can include a nucleic acid encoding a product of interest. For example, but not by way of limitation, an intercellular signaling system for use in biosensing can include (i) a first cell that (a) expresses a heterologous GPCR that binds an agent of interest and (b) expresses a secretable GPCR ligand upon binding the agent of interest; and (ii) a second cell that (a) expresses a heterologous GPCR that binds to the secretable GPCR ligand expressed by the first cell and (b) expresses a product of interest. In certain embodiments, the agent of interest is a human disease agent and the product of interest is a therapeutic for treating the human disease caused by the human disease agent.
In certain embodiments, the intercellular signaling systems of the present disclosure can be used for performing computations. Non-limiting examples of such computations include mathematical equations, logic gates and computational algorithms. In certain embodiments, an intercellular signaling system for performing computations can include a network in which different cells, e.g., yeast cells (e.g., genetically-engineered yeast cells), perform computation and where the information flow is done by the sensing (e.g., binding) and secretion of peptides and proteins by the different cells of the system. In certain embodiments, an intercellular signaling system having any type of network topology, as disclosed herein, can be utilized to perform computations, e.g., mathematical equations, logic gates and computational algorithms, where the cells of the system can sense one or more inputs, process the information and give one or more outputs. In certain embodiments, equations and algorithms can be used to predict and optimize the setup of any type of network in order to achieve desired input-output processing outcomes.
The present disclosure further provides kits to generate the intercellular signaling systems described herein. For example, a kit of the present disclosure can include one or more cells, one or more GPCR-encoding nucleic acids, one or more GPCR ligand-encoding nucleic acids, one or more essential gene-encoding nucleic acids and/or one or more nucleic acids that encode a product of interest disclosed herein.
In certain embodiments, a kit of the present disclosure can include a first container comprising at least one or more genetically-engineered cells disclosed herein. In certain embodiments, the genetically-engineered cell expresses a heterologous GPCR, e.g., encoded by a nucleic acid. In certain embodiments, the genetically-engineered cell expresses a GPCR ligand, e.g., encoded by a nucleic acid.
In certain embodiments, the first genetically-engineered cell includes (i) a nucleic acid encoding a heterologous G-protein coupled receptor (GPCR); and/or (ii) a nucleic acid encoding a secretable GPCR ligand. In certain embodiments, the kit can further comprise a second container that includes a second genetically-engineered cell comprising: (i) a nucleic acid encoding a heterologous GPCR; and/or (ii) a nucleic acid encoding a secretable GPCR ligand. In certain embodiments, the GPCR of the first and/or second cell is at least about 75% homologous to an amino acid sequence comprising any one of SEQ ID NOs: 117-161 and/or is encoded by a nucleotide sequence that is at least about 75% homologous to a nucleotide sequence comprising any one of SEQ ID NOs: 168-211. In certain embodiments, the heterologous GPCR of the first genetically-engineered cell is different than the heterologous GPCR of the second genetically-engineered cell, e.g., bind to different ligands. In certain embodiments, the secretable GPCR ligand of the first genetically-engineered cell is different than the secretable GPCR ligand of the second genetically-engineered cell, e.g., bind to different GPCRs.
Alternatively and/or additionally, a kit of the present disclosure can include one or more containers that include one or more components of an intercellular signaling system described herein. For example, but not by way of limitation, one or more containers can include one or more nucleic acids, e.g., vectors, that encode a heterologous GPCR and/or a secretable GPCR ligand.
A. The presently disclosed subject matter provides a genetically-engineered cell expressing at least one heterologous G-protein coupled receptor (GPCR), wherein the amino acid sequence of the heterologous GPCR is at least about 75% homologous to an amino acid sequence comprising any one of SEQ ID NOs: 117-161 or an amino acid sequence provided in Table 11 and/or is encoded by a nucleotide sequence that is at least about 75% homologous to a nucleotide sequence comprising any one of SEQ ID NOs: 168-211.
A1. The foregoing genetically-engineered cell, wherein the amino acid sequence of the heterologous GPCR is at least about 95% homologous to an amino acid sequence comprising any one of SEQ ID NOs: 117-161 or an amino acid sequence provided in Table 11 and/or is encoded by a nucleotide sequence that is at least about 95% homologous to a nucleotide sequence comprising any one of SEQ ID NOs: 168-211.
A2. The foregoing genetically-engineered cell of A and A1, wherein the heterologous GPCR is selectively activated by a ligand.
A3. The foregoing genetically-engineered cell of A2, wherein the ligand is selected from the group consisting of peptide, a protein or portion thereof, a small molecule, a nucleotide, a lipid, a chemical, a photon, an electrical signal and a compound.
A4. The foregoing genetically-engineered cell of A3, wherein the ligand is a compound.
A5. The foregoing genetically-engineered cell of A3, wherein the ligand is a protein or portion thereof.
A6. The foregoing genetically-engineered cell of A3, wherein the ligand is a peptide.
A7. The foregoing genetically-engineered cell of A6, wherein the peptide comprises about 3 to about 50 amino acid residues.
A8. The genetically-engineered cell of A6 or A7, wherein the amino acid sequence of the peptide is at least about 75% homologous to an amino acid sequence comprising any one of SEQ ID NOs: 1-72 or an amino acid sequence provided in Table 12.
A9. The foregoing genetically-engineered cell of any one of A6-A8, wherein the amino acid sequence of the peptide is at least about 95% homologous to an amino acid sequence comprising any one of SEQ ID NOs: 73-116 or an amino acid sequence provided in Table 12.
A10. The foregoing genetically-engineered cell of any one of A6-A9, wherein the peptide is encoded by a nucleotide sequence that is about 75% homologous to a nucleotide sequence comprising any one of SEQ ID NOs: 215-230.
A11. The foregoing genetically-engineered cell of any one of A-A10, wherein the cell further expresses at least one secretable GPCR ligand.
A12. The foregoing genetically-engineered cell of A11, wherein the at least one secretable GPCR ligand is a peptide or a protein or portion thereof.
A13. The foregoing genetically-engineered cell of A12, wherein the secretable GPCR ligand is a peptide.
A14. The foregoing genetically-engineered cell of A13, wherein the peptide comprises about 3 to about 50 amino acid residues.
A15. The foregoing genetically-engineered cell of any one of A11-A14, wherein the secretable GPCR ligand is identified and/or derived from a eukaryotic organism.
A16. The foregoing genetically-engineered cell of A15, wherein the eukaryotic organism is selected from the group consisting of an animal, plant, fungus and/or protozoan.
B. The presently disclosure provides a genetically-engineered cell expressing at least one heterologous secretable G-protein coupled receptor (GPCR) peptide ligand, wherein the amino acid sequence of the peptide is at least about 75% homologous to an amino acid sequence comprising any one of SEQ ID NOs: 1-72 or an amino acid sequence provided in Table 12.
B1. The foregoing genetically-engineered cell of B, wherein the amino acid sequence of the peptide is at least about 95% homologous to an amino acid sequence comprising any one of SEQ ID NOs: 73-116 or an amino acid sequence provided in Table 12.
B2. The foregoing genetically-engineered cell of B or B1, wherein the peptide is encoded by a nucleotide sequence that is about 75% homologous to a nucleotide sequence comprising any one of SEQ ID NOs: 215-230.
B3. The foregoing genetically-engineered cell of any one of B-B2, wherein the cell further expresses at least one heterologous G-protein coupled receptor (GPCR).
B4. The foregoing genetically-engineered cell of B3, wherein the heterologous GPCR is identified and/or derived from a eukaryotic organism.
B5. The foregoing genetically-engineered cell of B4, wherein the eukaryotic organism is selected from the group consisting of an animal, plant, fungus and/or protozoan.
B6. The foregoing genetically-engineered cell of any one of A-A16 and B-B5, wherein the genetically-engineered cell is selected from the group consisting of a mammalian cell, a plant cell and a fungal cell.
B7. The foregoing genetically-engineered cell of B6, wherein the genetically-engineered cell is a fungal cell.
B8. The foregoing genetically-engineered cell of B7, wherein the fungal cell is a species of the phylum Ascomycota.
B9. The foregoing genetically-engineered cell of B8, wherein the species of the phylum Ascomycota is selected from the group consisting of Saccharomyces cerevisiae, Saccharomyces castellii, Vanderwaltozyma polyspora, Torulaspora delbrueckii, Saccharomyces kluyveri, Kluyveromyces lactis, Zygosaccharomyces rouxii, Zygosaccharomyces bailii, Candida glabrata, Ashbya gossypii, Scheffersomyces stipites, Komagataella (Pichia) pastoris, Candida (Pichia) guilliermondii, Candida parapsilosis, Candida auris, Yarrowia lipolytica, Candida (Clavispora) lusitaniae, Candida albicans, Candida tropicalis, Candida tenuis, Lodderomyces elongisporous, Geotrichum candidum, Baudoinia compniacensis, Schizosaccharomyces octosporus, Tuber melanosporum, Aspergillus oryzae, Schizosaccharomyces pombe, Aspergillus (Neosartorya) fischeri, Pseudogymnoascus destructans, Schizosaccharomyces japonicus, Paracoccidioides brasiliensis, Mycosphaerella graminicola, Penicillium chrysogenum, Aspergillus nidulans, Phaeosphaeria nodorum, Hypocrea jecorina, Botrytis cinereal, Beauvaria bassiana, Neurospora crassa, Sporothrix scheckii, Magnaporthe oryzea, Dactylellina haptotyla, Fusarium graminearum, Capronia coronate and combinations thereof.
C. The present disclosure further provides an intercellular signaling system comprising one or more genetically-engineered cells of any one of A-A16 and B-B9.
C1. The foregoing intercellular signaling system of C, wherein the heterologous GPCR is activated by an exogenous ligand.
C2. The foregoing intercellular signaling system of C1, wherein the exogenous ligand is selected from the group consisting of a peptide, a protein or portion thereof, a small molecule, a nucleotide, a lipid, chemicals, a photon, an electrical signal and a compound.
C3. The foregoing intercellular signaling system of C2, wherein the exogenous ligand is a peptide.
D. The presently disclosed subject matter provides for an intercellular signaling system comprising: (a) a first genetically-engineered cell expressing at least one secretable G-protein coupled receptor (GPCR) ligand; and (b) a second genetically-engineered cell expressing at least one heterologous GPCR, wherein the amino acid sequence of the at least one heterologous GPCR is at least about 75% homologous to an amino acid sequence comprising any one of SEQ ID NOs: 117-161 or an amino acid sequence provided in Table 11 and/or is encoded by a nucleotide sequence that is at least about 75% homologous to a nucleotide sequence comprising any one of SEQ ID NOs: 168-211, wherein the secretable GPCR ligand of the first genetically-engineered cell selectively activates the heterologous GPCR of the second genetically-engineered cell.
D1. The foregoing intercellular signaling system of D, wherein the amino acid sequence of the at least one heterologous GPCR is at least about 95% homologous to an amino acid sequence comprising any one of SEQ ID NOs: 117-161 or an amino acid sequence provided in Table 11 and/or is encoded by a nucleotide sequence that is at least about 95% homologous to a nucleotide sequence comprising any one of SEQ ID NOs: 168-211.
D2. The foregoing intercellular signaling system of any one of D or D1, wherein the secretable GPCR ligand is identified and/or derived from a eukaryotic organism.
D3. The foregoing intercellular signaling system of D2, wherein the eukaryotic organism is selected from the group consisting of an animal, plant, fungus and/or protozoan.
D4. The foregoing intercellular signaling system of any one of D-D3, wherein the secretable GPCR ligand is selected from the group consisting of a protein or portion thereof and a peptide.
D5. The foregoing intercellular signaling system of D4, wherein the secretable GPCR ligand is a protein or portion thereof.
D6. The foregoing intercellular signaling system of D4, wherein the secretable GPCR ligand is a peptide.
D7. The foregoing intercellular signaling system of D6, wherein the peptide comprises about 3 to about 50 amino acid residues.
D8. The foregoing intercellular signaling system of D6 or D7, wherein the peptide is at least about 75% homologous to an amino acid sequence comprising any one of SEQ ID NOs: 1-72 or an amino acid sequence provided in Table 12.
D9. The foregoing intercellular signaling system of any one of D6-D8, wherein the peptide is at least about 95% homologous to an amino acid sequence comprising any one of SEQ ID NOs: 73-116 or an amino acid sequence provided in Table 12.
D10. The foregoing intercellular signaling system of any one of D6-D9, wherein the peptide is encoded by a nucleotide sequence that is about 75% homologous to a nucleotide sequence comprising any one of SEQ ID NOs: 215-230.
E. The present disclosure further provides an intercellular signaling system comprising: (a) a first genetically-engineered cell expressing at least one secretable G-protein coupled receptor (GPCR) peptide ligand; and (b) a second genetically-engineered cell expressing at least one heterologous GPCR, wherein the amino acid sequence of the secretable GPCR peptide ligand is at least about 75% homologous to an amino acid sequence comprising any one of SEQ ID NOs: 1-72 or an amino acid sequence provided in Table 12 and/or is encoded by a nucleotide sequence that is about 75% homologous to a nucleotide sequence comprising any one of SEQ ID NOs: 215-230, wherein the secretable GPCR ligand of the first genetically-engineered cell selectively activates the heterologous GPCR of the second genetically-engineered cell.
E1. The foregoing intercellular signaling system of E, wherein the heterologous GPCR is identified and/or derived from a eukaryotic organism.
E2. The foregoing intercellular signaling system of E1, wherein the eukaryotic organism is selected from the group consisting of an animal, plant, fungus and/or protozoan.
E3. The foregoing intercellular signaling system of any one of D-D10 and E-E2, wherein the second genetically-engineered cell further expresses at least one secretable GPCR ligand, and wherein the secretable GPCR ligand expressed by the second genetically-engineered cell is different from the secretable GPCR ligand expressed by the first genetically-engineered cell, e.g., selectively activate different GPCRs.
E4. The foregoing intercellular signaling system of any one of D-D10 and E-E3, wherein the first genetically-engineered cell further expresses at least one heterologous GPCR, wherein the heterologous GPCR expressed by the first genetically-engineered cell is different from the heterologous GPCR expressed by the second genetically-engineered cell, e.g., are selectively activated by different ligands.
E5. The foregoing intercellular signaling system of E3 or E4, wherein the secretable GPCR ligand expressed by the second genetically-engineered cell does not activate the heterologous GPCR expressed by the second genetically-engineered cell and/or does not activate the heterologous GPCR expressed by the first genetically-engineered cell.
E6. The foregoing intercellular signaling system of E5, wherein the secretable GPCR ligand expressed by the second genetically-engineered cell does not activate the heterologous GPCR expressed by the second genetically-engineered cell and activates the heterologous GPCR expressed by the first genetically-engineered cell.
F. The present disclosure provides an intercellular signaling system comprising: (a) a first genetically-engineered cell expressing at least one heterologous G-protein coupled receptor (GPCR); and (b) a second genetically-engineered cell expressing at least one secretable GPCR ligand, wherein the amino acid sequence of the at least one heterologous GPCR is at least about 75% homologous to an amino acid sequence comprising any one of SEQ ID NOs: 117-161 or an amino acid sequence provided in Table 11 and/or is encoded by a nucleotide sequence that is at least about 75% homologous to a nucleotide sequence comprising any one of SEQ ID NOs: 168-211, wherein the secretable GPCR ligand of the second genetically-engineered cell does not activate the heterologous GPCR of the first genetically-engineered cell.
F1. The foregoing intercellular signaling system of F, wherein the amino acid sequence of the at least one heterologous GPCR is at least about 95% homologous to an amino acid sequence comprising any one of SEQ ID NOs: 117-161 or an amino acid sequence provided in Table 11 and/or is encoded by a nucleotide sequence that is at least about 95% homologous to a nucleotide sequence comprising any one of SEQ ID NOs: 168-211.
F2. The foregoing intercellular signaling system of any one of F or F1, wherein the secretable GPCR ligand is identified and/or derived from a eukaryotic organism.
F3. The foregoing intercellular signaling system of F2, wherein the eukaryotic organism is selected from the group consisting of an animal, plant, fungus and/or protozoan.
F4. The foregoing intercellular signaling system of any one of F-F3, wherein the secretable GPCR ligand is selected from the group consisting of a protein or portion thereof and a peptide.
F5. The foregoing intercellular signaling system of F4, wherein the secretable GPCR ligand is a protein or portion thereof.
F6. The foregoing intercellular signaling system of F4, wherein the secretable GPCR ligand is a peptide.
F7. The foregoing intercellular signaling system of F6, wherein the peptide comprises about 3 to about 50 amino acid residues.
F8. The foregoing intercellular signaling system of any one of F6 or F7, wherein the peptide is at least about 75% homologous to an amino acid sequence comprising any one of SEQ ID NOs: 1-72 or an amino acid sequence provided in Table 12.
F9. The foregoing intercellular signaling system of any one of F6-F8, wherein the peptide is at least about 95% homologous to an amino acid sequence comprising any one of SEQ ID NOs: 73-116 or an amino acid sequence provided in Table 12.
F10. The foregoing intercellular signaling system of any one of F6-F8, wherein the peptide is encoded by a nucleotide sequence that is about 75% homologous to a nucleotide sequence comprising any one of SEQ ID NOs: 215-230.
G. The present disclosure further provides an intercellular signaling system comprising: (a) a first genetically-engineered cell expressing at least one heterologous G-protein coupled receptor (GPCR); and (b) a second genetically-engineered cell expressing at least one secretable GPCR peptide ligand, wherein the amino acid sequence of the secretable GPCR peptide ligand is at least about 75% homologous to an amino acid sequence comprising any one of SEQ ID NOs: 1-72 or an amino acid sequence provided in Table 12 and/or is encoded by a nucleotide sequence that is about 75% homologous to a nucleotide sequence comprising any one of SEQ ID NOs: 215-230, wherein the secretable GPCR ligand of the second genetically-engineered cell does not activate the heterologous GPCR of the first genetically-engineered cell.
G1. The foregoing intercellular signaling system of G, wherein the heterologous GPCR is identified and/or derived from a eukaryotic organism.
G2. The foregoing intercellular signaling system of G1, wherein the eukaryotic organism is selected from the group consisting of an animal, plant, fungus and/or protozoan.
G3. The foregoing intercellular signaling system of any one of F-F10 and G-G2, wherein the heterologous GPCR is activated by an exogenous ligand.
G4. The foregoing intercellular signaling system of G3, wherein the exogenous ligand is selected from the group consisting of a peptide, a protein or portion thereof, a small molecule, a nucleotide, a lipid, chemicals, a photon, an electrical signal and a compound.
G5. The foregoing intercellular signaling system of G4, wherein the exogenous ligand is a peptide.
G6. The foregoing intercellular signaling system of any one of F-F10 and G-G5, wherein the first genetically-engineered cell further expresses at least one secretable GPCR ligand, and wherein the secretable GPCR ligand expressed by the second genetically-engineered cell is different from the secretable GPCR ligand expressed by the first genetically-engineered cell, e.g., selectively activate different GPCRs.
G7. The foregoing intercellular signaling system of any one of F-F10 and G-G6, wherein the second genetically-engineered cell further expresses at least one heterologous GPCR, wherein the heterologous GPCR expressed by the first genetically-engineered cell is different from the heterologous GPCR expressed by the second genetically-engineered cell, e.g., are selectively activated by different ligands.
G8. The foregoing intercellular signaling system of any one of F-F10 and G-G7, wherein the first genetically-engineered cell and the second genetically-engineered cell are cells independently selected from the group consisting of mammalian cells, plant cells, fungal cells and combinations thereof.
G9. The foregoing intercellular signaling system of G8, wherein the first genetically-engineered cell and the second genetically-engineered cell are fungal cells.
G10. The foregoing intercellular signaling system of G9, wherein the first genetically-engineered cell and the second genetically-engineered cell are fungal cells independently selected from any species of the phylum Ascomycota.
G11. The foregoing intercellular signaling system of G10, wherein the first genetically-engineered cell and the second genetically-engineered cell are independently selected from the group consisting of Saccharomyces cerevisiae, Saccharomyces castellii, Vanderwaltozyma polyspora, Torulaspora delbrueckii, Saccharomyces kluyveri, Kluyveromyces lactis, Zygosaccharomyces rouxii, Zygosaccharomyces bailii, Candida glabrata, Ashbya gossypii, Scheffersomyces stipites, Komagataella (Pichia) pastoris, Candida (Pichia) guilliermondii, Candida parapsilosis, Candida auris, Yarrowia lipolytica, Candida (Clavispora) lusitaniae, Candida albicans, Candida tropicalis, Candida tenuis, Lodderomyces elongisporous, Geotrichum candidum, Baudoinia compniacensis, Schizosaccharomyces octosporus, Tuber melanosporum, Aspergillus oryzae, Schizosaccharomyces pombe, Aspergillus (Neosartorya) fischeri, Pseudogymnoascus destructans, Schizosaccharomyces japonicus, Paracoccidioides brasiliensis, Mycosphaerella graminicola, Penicillium chrysogenum, Aspergillus nidulans, Phaeosphaeria nodorum, Hypocrea jecorina, Botrytis cinereal, Beauvaria bassiana, Neurospora crassa, Sporothrix scheckii, Magnaporthe oryzea, Dactylellina haptotyla, Fusarium graminearum, Capronia coronate and combinations thereof.
G12. The foregoing intercellular signaling system of any one of D-D10, E-E6, F-F10 and G-G11, wherein the at least one heterologous GPCR expressed by the first genetically-engineered cell and/or second genetically-engineered cell is encoded by a nucleic acid.
G13. The foregoing intercellular signaling system of any one of D-D10, E-E6, F-F10 and G-G12, wherein the at least one secretable GPCR ligand expressed by the first genetically-engineered cell and/or second genetically-engineered cell is encoded by a nucleic acid.
G14. The foregoing intercellular signaling system of any one of C-C3, D-D10, E-E6, F-F10 and G-G13, wherein one or more endogenous GPCR genes of the one or more genetically-engineered cells, the first genetically-engineered cell and/or the second genetically-engineered cell are knocked out.
G15. The foregoing intercellular signaling system of G14, wherein the one or more endogenous GPCR genes comprises an STE2 gene and/or an STE3 gene.
G16. The intercellular signaling system of any one of C-C3, D-D10, E-E6, F-F10 and G-G15, wherein one or more endogenous GPCR ligand genes of the one or more genetically-engineered cells, the first genetically-engineered cell and/or the second genetically-engineered cell are knocked out.
G17. The foregoing intercellular signaling system of G16, wherein the one or more of the endogenous GPCR ligand genes comprises an MFA1/2 gene, an MFALPHA1/MFALPHA2 gene, a BAR1 gene and/or an SST2 gene.
G18. The foregoing intercellular signaling system of any one of G14-G17, wherein a genetic engineering system is used to knock out the one or more endogenous GPCR genes and/or the one or more endogenous GPCR ligand genes.
G19. The foregoing intercellular signaling system of G18, wherein the genetic engineering system is selected from the group consisting of a CRISPR/Cas system, a zinc-finger nuclease (ZFN) system, a transcription activator-like effector nuclease (TALEN) system and interfering RNAs.
G20. The foregoing intercellular signaling system of G19, wherein the genetic engineering system is a CRISPR/Cas system.
G21. The foregoing intercellular signaling system of any one of C-C3, D-D10, E-E6, F-F10 and G-G20, wherein the one or more genetically-engineered cells, the first genetically-engineered cell and/or the second genetically-engineered cell further comprises a nucleic acid encoding an essential gene, a conditionally essential gene and/or a toxic gene.
G22. The foregoing intercellular signaling system of any one of C-C3, D-D10, E-E6, F-F10 and G-G21, wherein the one or more genetically-engineered cells, the first genetically-engineered cell and/or the second genetically-engineered cell further comprises a nucleic acid encoding an essential gene, a conditionally essential gene and/or a toxic gene.
G23. The foregoing intercellular signaling system of any one of C-C3, D-D10, E-E6, F-F10 and G-G22, wherein the one or more genetically-engineered cells, the first genetically-engineered cell and/or the second genetically-engineered cell further comprises a nucleic acid that encodes a product of interest.
G24. The foregoing intercellular signaling system of G23, wherein the product of interest is selected from the group consisting of hormones, toxins, receptors, fusion proteins, regulatory factors, growth factors, complement system factors, enzymes, clotting factors, anti-clotting factors, kinases, cytokines, CD proteins, interleukins, therapeutic proteins, diagnostic proteins, enzymes, antibiotics, biosynthetic pathways, antibodies and combinations thereof.
G25. The foregoing intercellular signaling system of any one of C-C3, D-D10, E-E6, F-F10 and G-G24, wherein the one or more genetically-engineered cells, the first genetically-engineered cell and/or the second genetically-engineered cell further comprises a nucleic acid that encodes a detectable reporter.
G26. The foregoing intercellular signaling system of any one of C-C3, D-D10, E-E6, F-F10 and G-G25, wherein the one or more genetically-engineered cells, the first genetically-engineered cell and/or the second genetically-engineered cell further comprises a nucleic acid that encodes a sensor.
G27. The foregoing intercellular signaling system of any one of D-D10, E-E6, F-F10 and G-G26 further comprising a third genetically-engineered cell, a fourth genetically-engineered cell, a fifth genetically-engineered cell, a sixth genetically-engineered cell, a seventh genetically-engineered cell, an eighth genetically-engineered cell or more, wherein each of the genetically-engineered cells expresses at least one heterologous GPCR and/or at least one secretable GPCR ligand, wherein each of the heterologous GPCRs are different, e.g., are selectively activated by different ligands, and/or each of the secretable GPCR ligands are different, e.g., selectively activate different GPCRs.
G28. The foregoing intercellular signaling system of G27, wherein (i) the secretable ligand expressed by the second cell selectively activates the GPCR expressed by the third cell; (ii) the secretable ligand expressed by the third cell selectively activates the GPCR expressed by the fourth cell; (iii) the secretable ligand expressed by the fourth cell selectively activates the GPCR expressed by the fifth cell; (iv) the secretable ligand expressed by the fifth cell selectively activates the GPCR expressed by the sixth cell; (v) the secretable ligand expressed by the sixth cell selectively activates the GPCR expressed by the seventh cell; and/or (vi) the secretable ligand expressed by the seventh cell selectively activates the GPCR expressed by the eight cell.
G29. The foregoing intercellular signaling system of G27, wherein the intercellular signaling system comprises a daisy chain network topology.
G30. The foregoing intercellular signaling system of G27, wherein the intercellular signaling system comprises a bus type network topology.
G31. The foregoing intercellular signaling system of G27, wherein the intercellular signaling system comprises a branched type network topology.
G32. The foregoing intercellular signaling system of G27, wherein the intercellular signaling system comprises a star type network topology.
G33. The foregoing intercellular signaling system of G27, wherein the intercellular signaling system comprises a daisy chain network topology, a bus type network topology, a branched type network topology, a ring network topology, a mesh network topology, a hybrid network topology, a star type network topology or a combination thereof.
H. The present disclosure further provides an intercellular signaling system comprising a first genetically-engineered cell comprising a nucleic acid encoding at least one first heterologous G-protein coupled receptor (GPCR), wherein the first heterologous GPCR is at least about 75% homologous to an amino acid sequence comprising any one of SEQ ID NOs: 117-161 or an amino acid sequence provided in Table 11 and/or is encoded by a nucleotide sequence that is at least about 75% homologous to a nucleotide sequence comprising any one of SEQ ID NOs: 168-211.
H1. The foregoing intercellular signaling system of H, wherein the amino acid sequence of the heterologous GPCR is at least about 95% homologous to an amino acid sequence comprising any one of SEQ ID NOs: 117-161 or an amino acid sequence provided in Table 11 and/or is encoded by a nucleotide sequence that is at least about 95% homologous to a nucleotide sequence comprising any one of SEQ ID NOs: 168-211.
H2. The foregoing intercellular signaling system of H or H1, wherein the heterologous GPCR is selectively activated by a ligand.
H3. The foregoing intercellular signaling system of H2, wherein the ligand is selected from the group consisting of peptide, a protein or portion thereof, a small molecule, a nucleotide, a lipid, a chemical, a photon, an electrical signal and a compound.
H4. The foregoing intercellular signaling system of H3, wherein the ligand is a compound.
H5. The foregoing intercellular signaling system of H3, wherein the ligand is a protein or portion thereof.
H6. The foregoing intercellular signaling system of H3, wherein the ligand is a peptide.
H7. The foregoing intercellular signaling system of H6, wherein the peptide comprises about 3 to about 50 amino acid residues.
H8. The foregoing intercellular signaling system of any one of H-H7, wherein the first genetically-engineered cell further comprises a nucleic acid encoding a first heterologous secretable GPCR ligand.
H9. The foregoing intercellular signaling system of H8, wherein the secretable GPCR ligand is identified and/or derived from a eukaryotic organism.
H10. The foregoing intercellular signaling system of H9, wherein the eukaryotic organism is selected from the group consisting of an animal, plant, fungus and/or protozoan.
I. The present disclosure provides an intercellular signaling system comprising a first genetically-engineered cell comprising a nucleic acid encoding at least one first secretable G-protein coupled receptor (GPCR) peptide ligand, wherein the amino acid sequence of the secretable GPCR peptide ligand is at least about 75% homologous to an amino acid sequence comprising any one of SEQ ID NOs: 1-72 or an amino acid sequence provided in Table 12.
I1. The foregoing intercellular signaling system of I, wherein the amino acid sequence of the secretable GPCR peptide ligand is at least about 95% homologous to an amino acid sequence comprising any one of SEQ ID NOs: 73-116 or an amino acid sequence provided in Table 12.
I2. The foregoing intercellular signaling system of I, wherein the secretable GPCR peptide ligand is encoded by a nucleotide sequence that is about 75% homologous to a nucleotide sequence comprising any one of SEQ ID NOs: 215-230.
I3. The foregoing intercellular signaling system of any one of I-I2, wherein the cell further comprises a nucleic acid that encodes at least one heterologous G-protein coupled receptor (GPCR).
I4. The foregoing intercellular signaling system of I3, wherein the heterologous GPCR ligand is identified and/or derived from a eukaryotic organism.
I5. The foregoing intercellular signaling system of I4, wherein the eukaryotic organism is selected from the group consisting of an animal, plant, fungus and/or protozoan.
I6. The foregoing intercellular signaling system of any one of H-H10 and I-I5, wherein the genetically-engineered cell is selected from the group consisting of a mammalian cell, a plant cell and a fungal cell.
I7. The foregoing intercellular signaling system of I6, wherein the genetically-engineered cell is a fungal cell.
I8. The foregoing intercellular signaling system of I7, wherein the fungal cell is a species of the phylum Ascomycota.
I9. The foregoing intercellular signaling system of I8, wherein the species of the phylum Ascomycota is selected from the group consisting of Saccharomyces cerevisiae, Saccharomyces castellii, Vanderwaltozyma polyspora, Torulaspora delbrueckii, Saccharomyces kluyveri, Kluyveromyces lactis, Zygosaccharomyces rouxii, Zygosaccharomyces bailii, Candida glabrata, Ashbya gossypii, Scheffersomyces stipites, Komagataella (Pichia) pastoris, Candida (Pichia) guilliermondii, Candida parapsilosis, Candida auris, Yarrowia lipolytica, Candida (Clavispora) lusitaniae, Candida albicans, Candida tropicalis, Candida tenuis, Lodderomyces elongisporous, Geotrichum candidum, Baudoinia compniacensis, Schizosaccharomyces octosporus, Tuber melanosporum, Aspergillus oryzae, Schizosaccharomyces pombe, Aspergillus (Neosartorya) fischeri, Pseudogymnoascus destructans, Schizosaccharomyces japonicus, Paracoccidioides brasiliensis, Mycosphaerella graminicola, Penicillium chrysogenum, Aspergillus nidulans, Phaeosphaeria nodorum, Hypocrea jecorina, Botrytis cinereal, Beauvaria bassiana, Neurospora crassa, Sporothrix scheckii, Magnaporthe oryzea, Dactylellina haptotyla, Fusarium graminearum, Capronia coronate and combinations thereof.
I10. The foregoing intercellular signaling system of any one of H-H10 and I-19 further comprising a second genetically-engineered cell.
I11. The foregoing intercellular signaling system of I10, wherein the second genetically-engineered cell comprises a nucleic acid encoding a second heterologous secretable GPCR ligand.
I12. The foregoing intercellular signaling system of I10 or I11, wherein the second genetically-engineered cell comprises a nucleic acid encoding a second heterologous GPCR.
I13. The foregoing intercellular signaling system of I12, wherein the first heterologous secretable ligand selectively activates the second heterologous GPCR.
J. The present disclosure provides an intercellular signaling system comprising: (a) a first genetically-engineered cell comprising: (i) a nucleic acid encoding a first heterologous G-protein coupled receptor (GPCR); and/or (ii) a nucleic acid encoding a first secretable GPCR ligand; and (b) a second genetically-engineered cell comprising: (i) a nucleic acid encoding a second heterologous GPCR; and/or (ii) a nucleic acid encoding a second secretable GPCR ligand, wherein the first GPCR and/or the second GPCR is at least about 75% homologous to an amino acid sequence comprising any one of SEQ ID NOs: 117-161 or an amino acid sequence provided in Table 11 and/or is encoded by a nucleotide sequence that is at least about 75% homologous to a nucleotide sequence comprising any one of SEQ ID NOs: 168-211, and/or wherein the first and/or second secretable GPCR peptide ligand is at least about 75% homologous to an amino acid sequence comprising any one of SEQ ID NOs: 1-72 or an amino acid sequence provided in Table 12 and/or is encoded by a nucleotide sequence that is about 75% homologous to a nucleotide sequence comprising any one of SEQ ID NOs: 215-230.
J1. The foregoing intercellular signaling system of J, wherein the first secretable GPCR ligand of the first genetically-engineered cell selectively activates the second heterologous GPCR of the second genetically-engineered cell.
J2. The foregoing intercellular signaling system of J, wherein the second secretable GPCR ligand of the second genetically-engineered cell selectively activates the first heterologous GPCR of the first genetically-engineered cell.
J3. The foregoing intercellular signaling system of J, wherein the second secretable GPCR ligand of the second genetically-engineered cell selectively does not activate the first heterologous GPCR of the first genetically-engineered cell.
J4. The foregoing intercellular signaling system of any one of J-J3, wherein the first GPCR and the second GPCR are selectively activated by different ligands.
J5. The foregoing intercellular signaling system of any one of J-J4 further comprising a third genetically-engineered cell, wherein the third genetically-engineered cell comprises: (i) a nucleic acid encoding a third heterologous GPCR; and/or (ii) a nucleic acid encoding a third secretable GPCR ligand.
J6. The foregoing intercellular signaling system of J5, wherein the second secretable GPCR ligand of the second genetically-engineered cell selectively activates the third heterologous GPCR of the third genetically-engineered cell.
J7. The foregoing intercellular signaling system of J5 or J6, wherein the first secretable GPCR ligand of the first genetically-engineered cell selectively activates the third heterologous GPCR of the third genetically-engineered cell.
K. The present disclosure provides a kit comprising a genetically-modified cell of any one of A-A16 and B-B9.
L. The present disclosure further provides kit comprising an intercellular signaling system of any one of C-C3, D-D10, E-E6, F-F10, G-G33, H-H10, I-I13 and J-J7.
M. The present disclosure provides a method of using an intercellular signaling system of any one of C-C3, D-D10, E-E6, F-F10, G-G33, H-H10, I-I13 and J-J7 for the generation of pharmaceuticals.
N. The present disclosure provides a method of using an intercellular signaling system of any one of C-C3, D-D10, E-E6, F-F10, G-G33, H-H10, I-I13 and J-J7 for spatial control of gene expression and/or temporal control of gene expression.
O. The present disclosure provides a method of using an intercellular signaling system of any one of C-C3, D-D10, E-E6, F-F10, G-G33, H-H10, I-I13 and J-J7 for the generation of product of interest.
P. The present disclosure provides a method for the identification of a G-protein coupled receptor (GPCR) to be expressed in a genetically-engineered cell, comprising searching a protein and/or genomic database and/or literature for a protein and/or a gene with homology to S. cerevisiae Ste2 receptor and/or Ste3 receptor.
P1. The foregoing method of P, wherein the identified GPCR has an amino acid sequence that is at least about 15% homologous to the S. cerevisiae Ste2 receptor and/or Ste3 receptor.
Q. The present disclosure provides a method for the identification of a G-protein coupled receptor (GPCR) to be expressed in a genetically-engineered cell, comprising searching a protein and/or genomic database and/or literature for a protein and/or a gene with homology to (a) a GPCR comprising an amino acid sequence comprising any one of SEQ ID NOs: 117-161; (b) a GPCR comprising an amino acid sequence provided in Table 11; and/or (c) a GPCR encoded by a nucleotide sequence comprising any one of SEQ ID NOs: 168-211.
Q1. The method of Q, wherein the identified GPCR has an amino acid sequence that is at least about 15% homologous to the GPCR comprising an amino acid sequence comprising any one of SEQ ID NOs: 117-161 and/or the GPCR comprising an amino acid sequence provided in Table 11.
Q2. The method of Q, wherein the identified GPCR has a nucleotide sequence that is at least 15% homologous to the GPCR encoded by a nucleotide sequence comprising any one of SEQ ID NOs: 168-211.
R. The present disclosure provides a method for the identification of a GPCR ligand to be expressed in a genetically-engineered cell, comprising searching a protein and/or genomic database and/or literature for a protein, peptide and/or a gene with homology to: (i) a GPCR peptide ligand comprising an amino acid sequence comprising any one of SEQ ID NOs: 1-116; (ii) a GPCR peptide ligand comprising an amino acid sequence provided in Table 12; (iii) a GPCR peptide ligand encoded by a nucleotide sequence comprising any one of SEQ ID NOs: 215-230; and/or (iv) a yeast pheromone or a motif thereof.
R1. The method of R, wherein the identified GPCR ligand has an amino acid sequence that is at least about 15% homologous to (i) the GPCR peptide ligand comprising an amino acid sequence comprising any one of SEQ ID NOs: 1-116; (ii) the GPCR peptide ligand comprising an amino acid sequence provided in Table 12; (iii) the GPCR peptide ligand encoded by a nucleotide sequence comprising any one of SEQ ID NOs: 215-230; and/or (iv) the yeast pheromone or a motif thereof.
R2. The method of any one of P-P1, Q-Q2 and R-R1, wherein the protein and/or genomic database is selected from the group consisting of NCBI, Genbank, Interpro, PFAM, Uniprot and a combination thereof.
S. The present disclosure provides a genetically-engineered cell expressing a G-protein coupled receptor (GPCR) and/or a GPCR ligand identified by the method of any one of P-P1, Q-Q2 and R-R2.
The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the presently disclosed subject matter and are not intended to limit the scope of what the inventors regard as their presently disclosed subject matter. It is understood that various other implementations and embodiments can be practiced, given the general description provided herein.
The following methods were used in the Examples disclosed herein.
Strains. Yeast strains and the plasmids contained are listed in Table 2. All strains are directly derived from BY4741 (MATα leu2Δ0 met15Δ0 ura3Δ0 his3Δ1) and BY4742 (MATα leu2Δ0 lys2Δ0 ura3Δ0 his3Δ1) by engineered deletion using CRISPR Cas958,59.
Saccharomyces cerevisiae S288C: a useful set of strains and plasmids for
11
11
Media. Synthetic dropout media (SD) supplemented with appropriate amino acids; fully supplemented medium containing all amino acids plus uracil and adenine is referred to as synthetic complete (SC)60. Yeast strains were also cultured in YEPD medium61,62. Escherichia coli was grown in Luria Broth (LB) media. To select for E. coli plasmids with drug-resistant genes, carbenicillin (Sigma-Aldrich) or kanamycin (Sigma-Aldrich) were used at final concentrations of 75-200 μg/ml and 50 μg/ml respectively. Agar was added to 2% for preparing solid yeast media.
Materials. Synthetic peptides (≥95% purity) were obtained from GenScript (Piscataway, N.J., USA). S. cerevisiae alpha-factor was obtained from Zymo Research (Irvine, Calif., USA). Polymerases, restriction enzymes and Gibson assembly mix were obtained from New England Biolabs (NEB) (Ipswich, Mass., USA). Media components were obtained from BD Bioscience (Franklin Lakes, N.J., USA) and Sigma Aldrich (St. Luis, Mo., USA). Primers and synthetic DNA (gBlocks) were obtained from Integrated DNA Technologies (IDT, Coralville, Iowa, USA). Primers used in this study are listed in Table 10. Plasmids were cloned and amplified in E. coli C3040 (NEB). Sterile, black, clear-bottom 96-well microtiter plates were obtained from Corning (Corning Inc.).
Bioinformatic extraction of GPCR genes and peptide precursors. A database of fungal receptors was curated from the InterPro (IPR000366)63 and PFAM (PF02116) families64. Sequence identifiers were standardized using the UniProt ID mapping tool (http://www.uniprot.org/uploadlists/). UniProt IDs were used to programmatically retrieve associated taxonomic information. Taxonomic information was used to filter out non-fungal sequences and fragments. The amino acid sequences of the corresponding peptide ligands were derived in a similar approach. Sequences were validated by multiple sequence alignment using Clustal Omega65. The amino acid sequences, as well as the % identity for all Ste2-like GPCRs and peptide precursors are listed in Table 3, 4 and 9.
Saccharomyces
cerevisiae
Saccharomyces
cerevisiae
Vanderwaltozyma
polyspora2
Vanderwaltozyma
polyspora1
Torulaspora
delbrueckii
Saccharomyces
kluyveri
Kluyveromyces
lactis
Zygosaccharomyces
rouxii
Zygosaccharomyces
bailii
Candida glabrata
Ashbya gossypii
Scheffersomyces
stipitis
Komagataella
Candida (Pichia)
guilliermondii
Candida
parapsilosis
Candida auris
Yarrowia
lipolytica
Candida
lusitaniae
Candida albicans
Candida tropicalis
Candida tenuis
Lodderomyces
elongisporous
Geotrichum
candidum
Baudoinia
compniacensis
Schizosaccharomyces
octosporus
Tuber melanosporum
Aspergillus oryzae
Schizosaccharomyces
pombe
Aspergillus
fischeri
Pseudogymnoascus
destructans
Schizosaccharomyces
japonicus
Paracoccidioides
brasiliensis
Mycosphaerella
graminicola
Penicillium
chrysogenum
Aspergillus
nidulans
Phaeosphaeria
nodorum
Hypocrea jecorina
Botrytis cinerea
Beauvaria bassiana
Neurospora crassa
Sporothrix
scheckii
Magnaporthe oryzea
Dactylellina
haptotyla
Fusarium
graminearum
Capronia coronata
CYMLKRAADASDEVRRSASAVAEAVAEAFP
HHGQSM
CRFAGRICPPT
KRTADALNFVKREAEAVAE
GCYMLKRAADASGDVRRSAEALSEAMPDAE
QTPKCWKLLADEDGELSKRWCMRPGQPCWK
RSVDEHGDLAKRWCMRPGQPCWKAKRAAES
RPGQPCRKNKRAAEAVAEAFAEPWCGRPGQ
PC
KRDAEADVSEAAIKRCNMVGGACFEAKR
GQPC
KREALAEAEAWCGRPGQPCKREALAE
READPEAEAWCGRPGQPCRAVKRAAEAIAE
GVPGSSCNK
KREADPGYGWIGRCGVPGSSC
NKKRDEDAAAREHWLAQREAGGWIGRCGVP
GSSCNKKREEEVEVLRREAEAGGWIGRCGV
PGSSCNKARDANPGGWIGRCGVPGSSCNKK
LTNFGYFEPG
KRDANADAGFRLTNFGYFEP
G
KRDANAEAGFRLTNFGYFEPGK
WLRFFPGEPFVKRDAEADAEAKWGWLRFFP
GEPFVKRDADAEAKWGWLRFYPGEPFVKRE
SYWKGVNDGGSS
KREAAPEPEPEPEPGLSY
WKGVNDGGSS
KR
GLSYWKGVNDGGSS
KREA
RLRKGQGLF
TYWFFQPIMKRGEEETSEVVKREAKKNSRF
LTYWFFQPIMKREEDIVAGDEMVKREAKKN
SRFLTYWFFQPIMKREGGNEVEKRDAKKNS
RWINFRNTDVIGKREAQE
PIS
KRDADADADADAFSWNYRLKWQPISKR
KRDIGDEEDIVDAEKRDAAKFKFRLTRYGW
FSPN
KRELAEEEETVDAEKRDAAKFKFRLT
RYGWFSPN
KREVAEENDIVEKRDAAKFKFR
LTRYGWFSPN
YNSCPKTKREAQPEPTAAPEPVIPDHIQAR
YNSCPKTKREAAPAPAPTAAPEPVIPAHIQ
W
KEKMKMAKREAQPEPEAVAAPEPDPVAEP
TWKGQPCW
KEKMAKREAKPEPWCWWKGQPC
W
KAKRDAAPEPWCWWKGQPCWKAKRNAAPE
WYVPRPGDPAMKKRDALADANPDANPVE
KR
WCWILGGKCWKTKRVAEAVLSATIEGDE
LRPGQPIF
KREANPEAEADAKPSAWSWITL
RPGQPIF
REAEAEAEAEAEAEAEAEAFRWRNNEKNQP
FG
KREAEAEAEAEAEAEAEAFRWRNNEKNQ
PFG
KREAEAEAEAEAFRWRNNEKNQPFGKR
WRNNEKNQPFG
KREASIDTGTDDGAYWSWR
KRDIIEVGESVEEAVHDVYAREAEAEADPK
CRIHGQSCWKVKRVADAFANAIQGMGGLPP
QSCW
KRDALPEAEPQWCRIHGQSCWKKRDA
RDPQVCNMRLHPKKVCWKRDASPEAACNAP
LGQPCDKV
KRAAEAFAEAFDEPIAEAEAFD
HTVADANPEAEAFFD
KLAIDEAFPEPEAVA
DAEIADKV
KREAEAEAFCWRPGQPCGKVKR
CGHIGQGC
KRTTDASLDVKRSADALAEAMA
HWLQLKPGQPMY
KREAEAEAWHWLQLKPGQ
PMY
KREADAEAWHWLQLKPGQPMY
WHWLRLDPGQPLY
KREAEADAEANWHWLRL
DPGQPLY
KREADADAEANWHWLRLDPGQPL
Y
KREADADAEANWHWLRLDPGQPLY
HWWNFRNPDTANLKKRALTDAQEEEAESEM
GEPMY
NGWRYRPYGLPVG
KREAEAKYNGWRYRPYG
LPVG
KREAEADASAEARYNGWRYRPYGLPV
GR
QNPDRPDLK
KRDVPELPSKTYEDFLRVYKN
VYQNWETFQNPDRPDLKKRDVPELPSKTYE
DFLRVYKNWWSFQNPDRPDLKKRDVPELPS
PDRPNLKKRTEEDEENEEEDEEYYRFLQFY
PGRGAY
RRSAEAWHPRAGPPAYTLSKRDAA
REAKADAWHWLELDNGQPIYKREANAEAKP
WHWLELDNGQPIY
KREAKAEAKADAWHWLE
LDNGQPIY
KREAKAEAKADAWHWLELDNGQ
PIY
KREAEAKAGAWHWLELDNGQPIY
KREASPEAWRWFWLPGYGEPNWKRDAMPAD
KRDAMPADMDKEKREANPEAWRWFWLPGYG
EPNW
MRFSITLCSTLCALTVAAAPIEEYKRAPVA
SPGAAMF
KREAEADADAEAEAAPLVRLSPG
RLSPGAAMF
KRKAEADAEAEAPPLVRLSPG
Inference of the amino acid sequences of peptide ligands. The amino acid sequences of the mature peptide ligands were either taken from literature (Table 4) or predicted using the method reported by Martin et al66. In brief, mating pheromone precursor genes have a relatively conserved architecture. Genes encode for an N-terminal secretion signal (pre-sequence at the amino acid level), followed by repetitive sequences of the pro-peptide composed of non-homologous pro sequences, homologous sequences belonging to the presumptive signal peptide and protease processing sites. Based on this conserved arrangement, the actual sequence of the secreted peptide ligand can be predicted from the precursor sequence. Alignment with reported functional pheromone precursor sequences (from S. cerevisiae and C. albicans) facilitated annotation.
Construction of GPCR expression vectors. The GPCR expression vector is based on pRS416 (URA3 selection marker, CEN6/ARS4 origin of replication). All GPCRs were cloned under control of the constitutive S. cerevisiae TDH3 promoter and terminated by the S. cerevisiae STE2 terminator. Unique restriction sites (SpeI and XhoI) flanking the GPCR coding sequence were used to swap GPCR genes. Most GPCRs were codon-optimized for S. cerevisiae, DNA sequences were ordered as gBlocks, amplified with primers giving suitable homology overhangs and inserted into the linearized acceptor vector by Gibson Assembly. DNA sequences of all GPCR genes as well as the sequence of the full expression cassette (GPDp-xy.Ste2-Ste2t) integrated into the ΔSte2 locus are listed in Table 5.
Construction of peptide secretion vectors. The peptide secretion vector is based on pRS423 (HIS3 selection marker, 2μ origin of replication)58. The peptide coding sequence was designed based on the natural S. cerevisiae α-factor precursor, similar as described previously47. In brief: To make a general secretion cassette the MFα1 gene was amplified with or without the Ste13 processing site (EAEA). The actual sequences for the peptide ligands were inserted via a unique restriction site (AflII) after the pre- and pro-sequence, thus the peptide DNA sequence can be swapped by Gibson assembly67 using peptide-encoding oligos codon-optimized for expression in yeast. The DNA and resulting protein sequences of all peptide precursor genes are listed in Table 7. The constitutive ADH1 promoter or the ligand-dependent FUS1 and FIG1 promoters were used to drive peptide expression. Promoters were amplified from S. cerevisiae genomic DNA.
CRISPR-Cas9 system. The Cas9 expression plasmid was constructed by amplifying the Cas9 gene with TEF1 promoter and CYC1 terminator from p414-TEF1p-Cas9-CYC1t59 cloned into pAV11568 using Gibson assembly67. For short genes, MFALPHA1/2 and MFA1/2, a single gRNA was cloned into a gRNA acceptor vector (pNA304) engineered from p426-SNR52p-gRNA.CAN1.Y-SUP4t69 to substitute the existing CAN1 gRNA with a NotI restriction site. gRNAs were cloned into the NotI sites using Gibson assembly67. Double gRNAs acceptor vector (pNA0308) engineered from pNA304 cloned with the gRNA expression cassette from pRPR1gRNAhandleRPR1t70 with a HindIII site for gRNA integration. gRNAs were cloned into the NotI and HindIII sites using Gibson assembly67. For engineering yeast using the Cas9 system, cells were first transformed with the Cas9 expressing plasmid. Following a co-transformation of the gRNA carrying plasmid and a donor fragment. Clones were then verified using colony PCR with appropriate primers.
Construction of core peptide/GPCR language S. cerevisiae acceptor strains. Core S. cerevisiae strains yNA899 and yNA903 are derivatives of strain BY4741 (MATa leu2Δ0 met15Δ0 ura3Δ0 his3Δ1) and BY4742 (MATα lys2Δ0 leu2Δ0 ura3Δ0 his3Δ1), respectively. They are deleted for both S. cerevisiae mating GPCR genes (stet and ste3) and all mating pheromone-encoding genes (mfa1, mfa2, mfa1, mfa2) as well as for the genes far1, sst2 and bar1. All genes were deleted as clean open reading frame-deletions using CRISPR/Cas9 as described below. In most cases, except for MFA genes, two gRNAs were designed for each gene to target sequences on the 5′ and 3′ end of the gene's open reading frame (all gRNA sequences are listed in Table 8). Genes were deleted sequentially. After each round of gene deletion, strains were cured from the gRNA vector and directly used for deleting the next gene.
Genomic integration of color read-outs and GPCR genes. yNA899 was used to insert a FUS1 and a FIG1 promoter-driven yeast codon-optimized RFP (coRFP) into the HO locus. Using yeast Golden Gate (yGG) a transcription unit of the appropriate promoter (FUS1 or FIG1) was assembled with coRFP coding sequence and a CYC1 terminator into pAV10.HO5.loxP. Following yGG assembly and sequence verification, plasmid was digested with NotI restriction enzyme and transformed into yeast cells. Clones are then verified using colony PCR with appropriate primers. The resulting strain JTy014 was used for all GPCR characterizations by transforming it with the appropriate GPCR expression plasmids. GPCR genes were integrated into the ΔSte2 locus of yNA899. The GPDp-xySte2-Ste2t expression cassette for Bc.Ste2, Sc.Ste2 and Ca.Ste2 was used as repair fragment. The resulting generic locus sequence is listed in Table 5.
Construction of peptide-dependent yeast strains. yNA899 was used as parent. First, expression cassettes for Bc.Ste2 and Ca.Ste2 were integrated into the ΔSte2 locus as described above. The DNA binding domain of the pheromone-inducible transcription factor Ste12 (residues 1-215) was then replaced with the zinc-finger-based DNA binding domain 43-871 (the resulting Ste12 variant is referred to as orthogonal Ste12*,
GPCR on-off activity and dose response assay. GPCR activity and response to increasing dosage of synthetic peptide ligand was measured in strain JTy014 using the genomically integrated FUS1-promoter controlled coRFP as a fluorescent reporter. JTy014 strains carrying the appropriate GPCR expression plasmid were assayed in 96-well microtiter plates using 200 μl total volume, cultured at 30° C. and 800 RPM. Cells were seeded at an A600 of 0.3 (Note: all herein reported cell density values are based on A600 measurements in 96-well plates of a 200 μl volume of cultures with a path length of ˜0.3 cm performed in an Infinite M200 plate reader from Tecan) in SC media lacking uracil (selective component). All measurements were performed in triplicates. RFP fluorescence (excitation: 588 nm, emission: 620 nm) and culture turbidity (A600) were measured after 8 hours using an Infinite M200 plate reader (Tecan). Since the optical density values were outside the linear range of the photodetector, all optical density values were first corrected using the following formula to give true optical density values:
where Ameas is the measured optical density, Asat is the saturation value of the photodetector and k is the true optical density at which the detector reaches half saturation of the measured optical density36. Dose-response was measured at different concentrations (11 five-fold dilutions in H2O starting at 40 μM peptide, H2O was used as “no peptide” control) of the appropriate synthetic peptide ligand. All fluorescence values were normalized by the A600, and plotted against the log(10)-converted peptide concentrations. Data were fit to a four-parameter non-linear regression model using Prism (GraphPad) in order to extract GPCR-specific values for basal activation, maximal activation, EC50 and the Hill coefficient. Fold-activation was calculated for each GPCR as the maximum A600-normalized fluorescence of peptide-treated cells divided by the A600 normalized fluorescence value of water-treated cells.
GPCR orthogonality assay using synthetic peptides. GPCR activation was individually measured in 96-well microtiter plates in triplicate using each of the synthetic peptides (10 μM). Cells were seeded at an A600 of 0.3 in 200 μl total volume in 96-well microtiter plates, cultured at 30° C. and 800 rpm. Endpoint measurements were taken after 12 hours, as described above. Percent receptor activation was calculated by setting the A600-normalized fluorescence value of the maximum activation of each GPCR (not necessarily its cognate ligand) to 100% and the value of water treated-cells to 0%, with any negative values set to 0%).
Peptide secretion fluorescent halo assay. JTy014 was transformed with the appropriate GPCR expression plasmid and resulting strains were used as sensing strains. yNA899 was transformed with the appropriate peptide secretion plasmids and used as secreting strains. Sensing strains for all 16 peptides were individually spread on SC plates. Briefly, 0.5% agar was melted and cooled down to 48° C., cells are added to an aliquot of agar in a 1:40 ratio (100 μL of cells into 4 mL of agar for a 100 mm petri dish and 200 μL of cells into 8 mL of agar for a Nunc Omnitray), mixed well and poured on top of a plate containing solidified medium. A 10 μL dot of each of the secreting strains was spotted on each of the sensing strain plates. Plates were incubated at 30° C. for 24-48 h and imaged using a BioRad Chemidoc instrument and proper setting to visualized RFP signal (light source: Green Epi illumination and 695/55 filter).
Peptide secretion liquid culture assay. Peptide secretion in liquid culture was examined by co-culturing a secretion and a sensing strain (expressing the cognate GPCR) and measuring fluorescence of the induced sensing strain. Peptide secretion was under control of the constitutive ADH1 promoter. Secretion strains for each peptide were constructed by transforming yNA899 with the appropriate peptide expression construct (pRS423-ADH1p-xy.Peptide) along with an empty pRS416 plasmid. Sensor strains were constructed by transforming JTy014 with the appropriate GPCR expression construct (pRS416-GPD1p-xy.Ste2) along with an empty pRS423 plasmid. Matching the auxotrophic markers of the secretion and sensor strains allowed for robust co-culturing. Secreting and sensing strains were seeded in a 1:1 ratio each at an A600 of 0.15, and A600 and red fluorescence were measured after 12 hours. Experiments were run in triplicate. An unpaired t-test was performed for each peptide with an alpha value=0.05 to determine if differences in secretion between constructs containing or not containing the Ste13 processing site were significant. A single asterisk indicates a P value <0.05; a double asterisk indicates a P value <0.01.
Secretion orthogonality assay. The same sensing and secretion strains as described for the “Peptide secretion liquid culture assay” (above) were used to confirm orthogonality of secreted peptide in co-culture. Only the constructs that retained the Ste13 processing site were used. To determine orthogonality, each of the 16 constructed secretion strains were co-cultured 1:1 each at an A600 of 0.15 with the corresponding sensor strains to test for GPCR activation by non-cognate peptide, and A600 and red fluorescence were measured after 14 hours. Experiments were run in triplicate. Percent activation of the sensor strain was normalized by setting the maximum observed activation of the sensor strain (not necessarily by the cognate ligand) to 100%, and setting the basal fluorescence from co-culturing each sensor strain with a non-secreting strain to 0% activation, with any negative values set to 0%.
Transfer functions through minimal communication units. yNA899 with the appropriate GPCR integrated into the Ste2 locus using the CRISPR system described above were transformed with the appropriate peptide secretion plasmid (pRS423-FIG1p-xy.Peptide retaining the Ste3 processing site) and resulting strains were used as cell 1 (c1, sender). JTy014 was transformed with the appropriate GPCR expression plasmid (pRS416-GPD1p-xy.Ste2) and used as cell 2 (c2, reporter). As c1 and c2 didn't have the same auxotrophic markers, validated strains were grown overnight in selective media and then seeded at a 1:1 ratio each at an A600 of 0.15 in SC media. Cells were cultured in a total volume of 200 μl in 96-well microtiter plates and c1 was induced with the appropriate synthetic peptide at 2.5 nM, 50 nM, and 1000 nM, using water as the 0 nM control. Red fluorescence and A600 were measured after 12 hours. As a control, c2 was co-cultured with a non-secreting strain carrying an empty pRS423 plasmid and induced with the appropriate synthetic peptide at the concentrations listed above.
Multi-yeast paracrine ring assay. Communication loops were designed so that a single fluorescent measurement would indicate signal propagation through the full ring topology. An initiator strain was constructed by integrating the Ca.Ste2 into JTy014 and transforming it with a constitutive Kp peptide secretion plasmid (pRS423-ADH1p-Kp.Peptide). Linker strains from the transfer functions experiment (without a fluorescent readout) were used to complete each communication ring. Communication rings were seeded in triplicate at equal ratios (A600=0.02 each) in 10 mL selective 2×SC-His medium and incubated at 30° C. with 250 RPM shaking for 36 hours. 200 μL samples were taken for a fluorescent measurement of red fluorescence (588 nm/620 nm excitation/emission) in technical triplicate in a 96-well black clear-bottom plate and normalized by A600. To demonstrate that communication is contingent on a complete ring topology, a control with the first linker yeast strain in each ring dropped out was performed in parallel. The panels compare the normalized red fluorescent signal for each ring to the dropout control, with the fold change induction of the completed ring indicated.
Tree topology assay. Bus and tree topologies were designed so that a single fluorescent measurement would indicate signal propagation through the full topology. To enable branched topologies with two-input nodes, an additional orthogonal GPCR was integrated into the STE3 locus using the CRISPR-Cas9 system described above (strains ySB315 and ySB316, Table 2). Single and dual dose-response characteristics of ySB315 and ySB316 confirmed the ability to activate either or both co-expressed GPCRs (
Flow cytometry. Cells were seeded at an A600 of 0.3. Cells were exposed to the indicated peptide concentrations and cultured for 12 h in 96-well microtiter plates in a total volume of 200 μl at 30° C. and 800 RPM shaking. For each sample 50,000 cells were analyzed using a BD LSRII flow cytometer (excitation: 594 nm, emission: 620 nm). The fluorescence values were normalized by the forward scatter of each event to account for different cell size using FlowJo Software.
Peptide-dependence growth-assay. Strains ySB270, ySB265 and ySB188 were maintained on SD agar plates supplemented with 1 μM of Ca, Bc or Vp1 peptide. For assaying their peptide-dependent growth response, strains were cultured overnight in the presence of 100 nM peptide in SC-His. Cells were washed five times with one volume of water. Cells were than seeded in 200 μl SC (no selection) at an A600 of 0.06 and cultured at 30° C. and 800 RPM shaking. Cells were exposed to different concentrations of peptide (seven 10-fold dilutions starting from 1 μM, water was used for the “no-peptide” control). A600 was determined at various time points over the course of 24 h. The 24 h-data points were plotted against the log10 of the peptide concentrations. Data were fit to a four-parameter non-linear regression model using Prism (GraphPad) to extract values for peptide/growth EC50. For dot assays, serial 10-fold dilutions of overnight cultures of ySB270 and ySB265 were spotted on SD agar plates supplemented with or without 1 μM peptide and incubated at 30° C. for 48 hours.
2-Yeast and 3-Yeast interdependent co-culturing. Strains ySB270, ySB265 and ySB188 were transformed with the appropriate peptide secretion vectors (Bc, Ca or Vp1) featuring peptide expression under the constitutive ADH1 promoter. For assaying 2-Yeast interdependence, the resulting peptide-secreting strains (treated with peptide and washed as described above) were seeded in the appropriate combination in a 1:1 ratio in 200 μl SC-His at an A600 of 0.06 (0.03 each) and cultured at 30° C. and 800 RPM shaking. The same cell number of single strains was seeded alone and cultured in parallel as control. A600 measurements were taken at the indicated time points and cultures were diluted into fresh media when the culture reached an A600 of 0.8-1. For assaying 3-Yeast interdependence, the appropriate peptide secreting strains (c1, c2 and c3) were inoculated in a ratio of 1:1:1 in 200 μl SC-His media at an A600 of 0.06 (0.02 each) in a 96-well plate cultured at 30° C. and 800 RPM shaking. Experiments were run in triplicate. All three combinations of controls lacking one essential member (c1 omitted, c2 omitted, c3 omitted) were run in parallel. A600 measurements were taken at the indicated time points and cultures were diluted 1:20 into fresh media approximately every 12 hours. After 115 h the dilution rate was reduced to 1:20 every 24 hours. The total run time was 183 h (˜7.5 d). Samples were taken before every dilution. Samples were used to determine the co-culture composition and the peptide concentration as follows: De-convolution of strain identity: aliquots of the culture were plated on three different plate types, YPD containing either 1 μM Bc, Ca or Vp1 synthetic peptide. Each strain can only grow on plates containing its cognate peptide ligand. The co-culture composition was than determined by colony counting. Peptide concentration: JTy014 transformed with the appropriate GPCR was used as peptide sensor. The linear range of the GPCRs dose response was used for peptide quantification.
Engineering multicellularity is one of the aims of Synthetic Biology1-3. A bottleneck to effectively building multicellular systems can be the need for a scalable signaling language with a large number of interfaces that can be used simultaneously.
The transition from unicellular to multicellular organisms is considered one of the major transitions in evolution4. Phylogenetic inference suggests that cell-cell communication, cell-cell adhesion and differentiation constitute the key genetic traits driving this transition5. Accordingly, cell-cell communication plays an important role in many complex natural systems, including microbial biofilms6,7, multi-kingdom biomes8,9, stem cell differentiation10, and neuronal networks11. In nature, communication between species or cell types relies on a large pool of promiscuous and orthogonal communication interfaces, acting at both short and long ranges. Signals range from simple ions and small organic molecules up to highly information-dense macromolecules including RNA, peptides and proteins. This diverse pool of signals allows cells to process information precisely and robustly, enabling the emergence of properties, fate decisions, memory and the development of form and function.
In contrast, certain previous approaches to engineering synthetic biological communication mostly rely on a single signaling modality—quorum sensing (QS), a cell density-based communication system used by many bacteria12. The discovery of bacterial QS almost 50 years ago13 led to a paradigm shift in synthetic microbial ecology, enabling the engineering of systems with synthetic pattern formation14, cellular computing15,16, controlled population dynamics17,18 and emergent properties19. QS has been exported from bacteria into plants20 and mammalian cells21.
The major class of QS is based on diffusible acyl-homoserine lactone (AHL) signaling molecules generated by AHL synthases and AHL receptors that function as transcription factors, regulating gene expression in response to AHL signals.
While QS has been demonstrated to coordinate interactions both within a bacterial species and between species, a need exists for a method for conveying discrete and isolatable information using QS22 and it thus can be difficult to use this language for engineering scalable communities. A synthetic language should have a scalable set of independent interaction channels that do not have crosstalk.
However, the scalability of QS into many independent channels can be limited by the low information content that can be encoded in AHL signaling molecules, since these molecules are structurally and chemically simple and the receptors are known to be promiscuous.23,24 While crosstalk can be eliminated by receptor evolution25, the AHL ligand/receptor pairs are not well suited for rapid diversification into orthogonal channels by directed evolution because the AHL biosynthesis and receptor specificity would have to be engineered in concert. As a consequence, only four AHL synthase/receptor pairs are available for synthetic communication and only three have been successfully used together26; this shortage of QS interfaces limits the number of possible unique nodes in a synthetic cell community24.
In addition to AHL-based QS, communication has been engineered using autoinducer peptides (AIP)27 and autoinducer molecules (AI-2)28 from Gram-positive bacteria. Autoinducer peptides are a class of post-translationally modified peptides sensed by a membrane-bound two-component system29. AI-2 is a family of 2-methyl-2,3,3,4-tetrahydroxytetrahydrofuran or furanosyl borate diester isomers—synthesized by LuxS from S-ribosylhomocysteine followed by cyclization to the various AI-2 isoforms30,31—and recognized by the transcriptional regulator LsrR32. It was shown that the response characteristics and the promoter specificity of LsrR can be engineered33,34 and that cell-cell communication can be tuned by using various AI-2 analogues28.
However, the complexity of signal biosynthesis and reliance on specific transporters for signal import- and export32 can limit the scalability of these systems in terms of available unique communication interfaces.
Mammalian Notch receptors have been repurposed to engineer modular communication components for mammalian cells. Sixteen distinct SynNotch receptors were engineered and pairs of two where employed together35; however, SynNotch receptors are contact-dependent and therefore are only suitable for short-range communication, which is conceptually different from long-range communication through diffusible signals.
Because GPCRs couple well to the conserved yeast MAP-kinase signaling cascade36, it was hypothesized that the peptide/GPCR-based mating language of fungi could overcome certain limitations and be harnessed as a source of modular parts for a scalable intercellular signaling system. Fungi use peptide pheromones as signals to mediate species-specific mating reactions37. These peptides are genetically encoded, translated by the ribosome, and the alpha-factor-like peptides, which are typified by the 13-mer S. cerevisiae mating pheromone alpha-factor, and are secreted through the canonical secretion pathway without covalent modifications. Peptide pheromones are sensed by specific GPCRs (e.g., Ste2-like GPCRs) that initiate fungal sexual cycles38. The peptide pheromones (e.g., 9-14 amino acids in length) are rich in molecular information and the composition of peptide pheromone precursor genes is modular, consisting of two N-terminal signaling regions—“pre” and “pro”— that mediate precursor translocation into the endoplasmic reticulum and transiting to the Golgi, followed by repeats of the actual peptide sequence separated by protease processing sites. This modular precursor composition allows bioinformatic inference of mature peptide ligand sequences from available genomic databases. GPCRs from mammalian and fungal origin have been used on a small scale (two to three GPCRs) to engineer programmed behavior and communication39,40 and cellular computing41. However, leveraging the vast number of naturally-evolved mating peptide/GPCR pairs as a scalable signaling “language” remains an unmet need.
In order to challenge the inherent scalability of the fungal mating components as a synthetic signaling language, a pipeline for language component acquisition and communication assembly was established (
First, a total of 45 peptide/GPCR pairs from available Ascomycete genomes (Table 3) was mined; sequences of mature peptide ligands were taken from literature (Table 3) or inferred from peptide precursor sequences (Table 4). In some cases, inference of mature peptide sequences was hampered by ambiguous protease processing sites or sequence-variable peptide repeats. The GPCR's tolerance to sequence variation in its peptide ligands was evaluated by incorporating alternate peptide sequence candidates into the analysis (Table 3 and 4). Functionality of heterologous mating GPCRs in S. cerevisiae requires proper insertion into the membrane and coupling to the S. cerevisiae Gα subunit (
Genome-mined GPCRs showed amino acid sequence identities between 17-68% to the S. cerevisiae mating GPCR Ste2 (Table 3), but most of them showed higher conservation at specific intracellular loop motifs known to be important for Gα coupling42,43 (
Remarkably, 32 out of 45 tested GPCRs (73%) gave a strong fluorescence signal in response to their inferred synthetic peptide ligand (ligand candidate #1, Table 3 and 4) (
After initial on/off screening, dose-response curves were measured for all 32 functional GPCRs and extracted parameters crucial for establishing communication: Sensitivity of GPCRs (EC50), basal and maximal activation (fold-change activation), dynamic range (Hill coefficient), orthogonality, reversibility of signaling, and population response behavior (
Sensitivity of the GPCRs for their cognate ligand gave an EC50 range of ˜1 to 104 nM, with the natural S. cerevisiae Ste2 exhibiting the highest sensitivity of 1.25 nM. This is comparable to the sensitivity of available QS systems26. Functional GPCRs displayed between 1.3 and 17-fold activation. This range overlaps that of QS systems but is on average slightly lower than available QS systems26 but comparable to other engineered GPCR-based signaling systems in yeast and mammalian cells45,46 Response behaviors ranged from a graded response (analog) with a wide dynamic range to “switch-like” (digital) behavior with a very narrow dynamic range. When dose responses were characterized at the single-cell level, a subset of non-responding cells were observed, likely due to plasmid copy number noise (
Importantly, GPCR signaling can be de-activated and re-activated several times with either no or minimal lengthening of response time (
The GPCRs can also be co-expressed in a single cell in order to allow for processing of two separate signals by a single cell (
Next, pairwise orthogonality was assessed for a subset of 30 peptide/GPCR by exposing each GPCR to all non-cognate peptide ligands. The GPCRs showed a remarkable level of natural orthogonality (
Next, the robustness of the ability to infer a GPCR's peptide ligand was validated. Thus, dose-response curves were recorded for a subset of 19 GPCRs to possible alternative near-cognate peptide ligand candidates. 14 out of the 19 GPCRs were also activated by these near-cognate peptides (
In fact, near-cognate ligands can be harnessed to induce significant changes in EC50, fold activation, and dynamic range for most peptide/GPCR pairs (
After assessing peptide/GPCR functionality with synthetic peptides, it was tested whether the peptides can be functionally secreted. The feasibility of peptide secretion from S. cerevisiae through its conserved sec pathway has been shown before,47 but the feasibility across a wide sequence space was unclear. The amino acid sequences of 15 peptides were cloned into a peptide secretion vector, designed based on the alpha-factor pre-pro-peptide architecture (
To test for peptide secretion, the appropriate GPCR/fluorescent-readout strains were employed as peptide sensors in a liquid assay as well as a fluorescent halo assay. All peptides can be secreted from S. cerevisiae (
Next, functional communication was established by coupling GPCR signaling to peptide secretion. The language was conceptualized to be built from two-cell links as the minimal signaling units that can be easily characterized and assembled into higher-order communication topologies (
Next it was tested if the language can be used to link multiple yeast strains and build synthetic multicellular communities. The functional capabilities of single engineered organisms are limited by their capacity for genetic modification. Multi-membered microbial consortia engineered to cooperate and distribute tasks show promise to unlock this constraint in engineering complex behavior. For example, engineering sense-response consortia composed of yeast that sense a trigger, e.g., a pathogen36, and yeast that respond, e.g., by killing the pathogen through secretion of an antimicrobial48 is contemplated. Further, consortia have shown distinct advantages for metabolic engineering, such as distribution of metabolic burden, as well as parallelized, modular optimization and implementation49,50. Those consortia have applications in degrading complex biopolymers like lignin, cellulose51 or plastic52.
First, the established two-cell communication links were combined into a scalable paracrine ring topology. A ring is a network topology in which each cell cx connects to exactly two other cells (cx−1 and cx+1), forming a single continuous signal flow. The ring topology can be efficiently scaled by adding additional links. Failure of one of the links in the ring leads to complete interruption of information flow, allowing simultaneous monitoring of the functionality and continued presence of all ring members. The two-cell links were combined into rings of increasing size, from two to six members (
The differential growth phenotypes were partly caused by the expression and secretion burden of specific combinations of GPCRs and peptides. This can be addressed by improving expression and secretion levels. Growth phenotypes were also caused by GPCR-activation (and downstream activation of the mating response) and can be alleviated by using an orthogonal Ste12* that decouples GPCR-activation from the mating response (
Next, in order to test for inherent scalability, the number of members in the communication ring was increased stepwise from three to six members (
To test if a different interconnected communication topology can be achieved, a branched tree topology using cells co-expressing two GPCRs and accordingly being able to process two inputs (dual-input nodes) was also implemented. Such topologies allow integration of multiple information inputs and report on the presence of at least one of these distributed inputs. Functional signal flow was first tested through a three-yeast linear bus topology able to process two inputs (
Next, to anticipate a real application of the language, its orthogonal interfaces were leveraged to render yeast cells mutually dependent based on peptide signaling and essential gene activation.
Engineered interdependence is of central importance for synthetic ecology as the integrity of synthetic consortia can be enforced. Certain current approaches to engineer mutual dependence in synthetic communities rely on metabolite cross feeding50, which limits the number of members that can be rapidly added to such a microbial community, and can suffer from a dependence on cross feeding metabolically expensive molecules needed at substantial molar concentrations. The peptide signal-based interdependence is conceptually different from cross feeding metabolites as interfaces that are orthogonal to the cellular metabolism were used, that allow scaling the number of community members by peptide/GPCR gene swapping and which are sensitive enough to function at low nanomolar signal concentrations.
In order to engineer mutually dependent strain communities, an essential gene was placed under GPCR control (
As expected, the resulting strains were dependent on peptide for growth and showed peptide/growth EC50 values in the nanomolar range, which was achievable by secretion (
In summary, fungal mating peptide/GPCR pairs were repurposed into a scalable language with an extensible number of orthogonal interfaces—unique channels are one of the current bottlenecks in scaling the complexity of synthetic ecology communities.
The fungal pheromone response pathway constitutes an ideal source for a large pool of unique signal and receiver interfaces that can be harnessed to build this modular, synthetic communication language.
These interfaces are accessible by genome mining as both the peptides and the GPCRs are genetically encoded and can be implemented by simple gene cloning.
Genome mining alone yields a high number of off-the-shelf orthogonal interfaces whose component diversity can potentially be further scaled and tuned by directed evolution to exploit the full information density of 9-13 amino acid peptide ligands (sequence space >1014). Further, the language can be tuned by ligand recoding, as small changes in the sequence of a given peptide ligand alters the response behavior of a given GPCR. Importantly, changing the ligand sequence can be achieved by simple cloning and does not require receptor or metabolic engineering. In addition, peptides are technically ideal as a signal. Peptides are stable and rich in molecular information and virtually any short peptide sequence is readily available through commercial solid-phase synthesis allowing for the rapid characterization and evolution of new peptide-sensing mating GPCRs.
The peptide/GPCR language is modular and insulated, and thus likely portable to many other Ascomycete fungi as this is where the component modules are derived. Furthermore, as has been done for mammalian GPCRs in yeast, this system can be portable to animal and plant cells. Its simplicity suggests that the system will be easy for other laboratories to adopt, scale and customize, especially in the light of new tools for the rational tuning of GPCR-signaling in yeast.54
The language is compatible with existing and future synthetic biology tools for applications such as biosensing, biomanufacturing55,56 or building living computers41,57.
The disclosure of S. Billerbeck et al. (2018) Nature Communications volume 9, Article number: 5057, published Nov. 28, 2018, is incorporated by reference herein in its entirety.
The above disclosed subject matter is to be considered illustrative, and not restrictive, and the appended claims are intended to cover all such modifications, enhancements, and other implementations which fall within the true spirit and scope of the present disclosure. Thus, to the maximum extent allowed by law, the scope of the present disclosure is to be determined by the broadest permissible interpretation of the following claims and their equivalents and shall not be restricted or limited by the foregoing detailed description.
The contents of all figures and all references, patents and published patent applications and Accession numbers cited throughout this application are expressly incorporated herein by reference.
This application is a continuation of International Patent Application No. PCT/US2020/030795, filed Apr. 30, 2020, which claims priority to U.S. Provisional Application No. 62/840,812, filed on Apr. 30, 2019, the contents of each of which are incorporated by reference in their entireties, and to each of which priority is claimed.
This invention was made with government support under AI110794, GM066704, RR027050 awarded by the National Institutes of Health, 1144155 awarded by the National Science Foundation, and HR0011-15-2-0032 awarded by DOD/DARPA. The government has certain rights in the invention.
| Number | Date | Country | |
|---|---|---|---|
| 62840812 | Apr 2019 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | PCT/US2020/030795 | Apr 2020 | US |
| Child | 17514648 | US |
